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Plants and the fungi that colonize them (endophytic fungi) are prolific 
producers of the kinds of structurally interesting and biologically active small 
molecules (natural products) that captivate chemists and biologists alike. The work 
reported here focuses on the isolation of new natural products by two different yet 
complementary strategies. In the first, we sought new chemical diversity from a 
largely unexplored pool of biodiversity – the endophytic fungi. In the second, we 
examined a well-studied natural product reservoir – traditional Chinese medicinal 
plants – using new and innovative biological screens at the Institute of Chemistry and 
Cell Biology at Harvard Medical School. 
The isolation and structure determination of a new inhibitor of STAT3 
signaling from the Floridian endophytic fungus FA39 is described. FA39 showed 97% 
rDNA sequence identity to the ascomycete Phaeosphaeria avenaria. Bioassay-guided 
fractionation of FA39 yielded the STAT3 inhibitor phaeosphaeride A, and its inactive 
diastereomer phaeosphaeride B. 
The discovery of a new family of non-templated biopolyesters from the Costa 
Rican endophytic fungus CR873 is described. CR873 showed 99% rDNA sequence 
identity to the ascomycete Daldinia concentrica. This fungus produces large amounts 
of oligomers of (3R,5R)-3,5-dihydroxyhexanoic acid – the first example of a 
eukaryote that produces biopolyesters of this nature.  
The isolation and structure elucidation of two new cytokinesis-inhibitory 
cucurbitacins using a fluorescence imaging screen is described. The new cucurbitacins 
were isolated from Physocarpus capitatus along with a new biphenyl and the known 
compounds cucurbitacin F and 23,24-dihydrocucurbitacin F. Studies into the 
mechanism of action of the cucurbitacins are also reported. 
The isolation and structure elucidation of TRPV4 channel activators and the 
structure elucidation of an angiogenesis inhibitor from prefractionated traditional 
Chinese medicinal plants are described. TRPV4 activators kaikasaponin III from 
Sophora sp. and linoleic acid from Stellaria sp. and Fritillaria sp. were identified 
without any further chromatographic separation. The diterpene dimer 
bisandrographolide A was isolated from Andrographis sp. after a single round of 
HPLC and found to potently activate TRPV4 channels. Hydroferulic acid from 
Stellaria sp. was identified in a screen of angiogenesis inhibitors without any further 
chromatographic separation. Attempts to optimize the activity of hydroferulic acid are 
also described. 
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xi Chapter One 
New Landscapes and New Eyes: Approaches to Natural Products Discovery 
 
Leave the beaten track occasionally and dive into the woods. Every 
time you do so you will be certain to find something that you have 
never seen before. 
Alexander Graham Bell 
 
 
The real voyage of discovery consists not in seeking new landscapes  
but in having new eyes. 
Marcel Proust 
 
 
Natural products as drugs and probes for biology 
Natural products – often referred to as secondary metabolites, due to the 
absence of a role in the primary metabolism of the producing organism – are small 
organic molecules produced by living organisms. It is thought that these molecules 
confer a selective advantage on the producer by mediating interactions with other 
organisms, for example as a defense mechanism.
1  
The natural functions of secondary metabolites are relatively little studied, as 
most research focuses on their usefulness to mankind. Natural products are credited 
with doubling the lifespan of human beings.
2 More than half of the most prescribed 
drugs in the United States are natural products or natural product-derived,
3 accounting 
for over $16 billion in annual sales.
4 Contrary to the popular belief that secondary 
metabolites are only useful against their natural targets,
5 natural products display 
potent activity against a variety of human enzyme targets
6 and today the number of 
microbial natural products with non-antibiotic activity far exceeds the number of 
antibiotics.
7 The numbers are even more impressive for specific disease areas. When 
the data was last compiled, some 62% of all cancer drugs came from nature,
8 along 
with 79% of the top prescribed allergy and respiratory drugs, 75% of the top general 
1 medicine and analgesic drugs, and all of the top drugs for dermatology, gynecology, 
and hematology.
9 Natural products have also proven to be extremely useful as 
insecticides, herbicides, plant growth regulators, and as probes for understanding basic 
processes in biology.
10 We can expect that natural products will continue to provide 
new drugs into the future. In 2003, there were 15 new natural products in Phase III 
clinical trials, including new anticancer, antifungal, antibacterial, immunosuppressive 
and analgesic compounds.
11
Natural products are characterized by a number of specialized structural 
features that likely facilitate their potent and specific biological activity. They possess 
large numbers of hydrogen bond donors and acceptors balanced by lipophilic regions 
on a stereochemically complex surface, making them ideally suited for binding to 
protein targets.
12-14 Natural products also tend to be quite rigid – they contain large 
numbers of fused ring systems and high degrees of unsaturation, with few rotatable 
bonds.
12 The rigidity of natural products contributes to their protein binding affinity by 
reducing the entropic barrier to binding.
14
The evolutionary history of natural products has conferred upon them 
additional advantages for use in drug discovery. When necessary to reach their target, 
natural products are able to travel to the appropriate organ or cell and to penetrate cell 
membranes.
5 Natural products have also evolved ways to escape destruction or 
modification by enzymes in the target organism. Finally, as a consequence of their 
biosynthetic origins, bioactive natural products are often produced as families of 
related compounds,
15 which can be isolated and used in structure-activity relationship 
(SAR) studies. 
Despite the many advantages of natural products, they have fallen out of favor 
in most commercial drug discovery efforts due to problems with rediscovery of known 
structures, slow compound isolation, extract complexity, and resupply issues. 
2 The traditional approach of grinding up a whole organism and assaying the 
extract for activity (most often antibiotic activity) has yielded a steadily shrinking ratio 
of new molecules to known ones. In antibiotic assays it is estimated that less than 1 
out of every 500 active compounds is new,
16 and the process of rapidly identifying 
known molecules prior to detailed structure analysis, termed dereplication, has 
become a major focus.
17 In the words of the late marine natural products chemist John 
Faulkner, “the good old days of ‘grind and find’ – when nearly every organism 
contained new and interesting molecules – are fast disappearing. Most bioactive 
extracts now contain only known compounds and developing rapid methods to avoid 
duplication of earlier research has become a priority.”
18
The long timeframe from observation of bioactivity to identification of the 
pure compound responsible poses a significant obstacle to biological collaboration. 
Typically the isolation process involves repeated chromatography steps, each followed 
by a bioassay step to determine which fraction contains the bioactive molecule(s). 
Once a pure, active compound is obtained, nuclear magnetic resonance (NMR) 
spectroscopy, x-ray crystallography, and/or mass spectrometry are used to identify the 
structure. Major developments in these spectroscopic techniques have made the 
compound identification step quite rapid. However, bioassay-guided fractionation 
remains a major bottleneck in natural products screening. This concern is magnified 
by changes in the way pharmaceutical companies screen for new drugs. High-
throughput screening (HTS) has made it possible to assay huge numbers of 
compounds in a very short time, approaching 100,000 samples per day.
19 As a result, a 
screen for molecules against a given target may only run for a few weeks or even days 
– not long enough to do bioassay-guided fractionation of natural product extracts. 
Another perceived disadvantage of natural products is their ‘dirtiness’. Most 
natural products screening efforts use crude extracts of the producing organism, which 
3 often contain so-called nuisance compounds (e.g. polyphenols in plants) that show 
nonspecific activity in a variety of screens. In whole-cell or whole-organism screens, 
the undesired activity (e.g. cytotoxicity) of one compound in a crude extract can 
obscure the activity of interest exhibited by another compound.
20 Even after an active 
compound is successfully identified, supply issues may complicate further studies, as 
subsequent collections (or subcultures in the case of microorganisms) of the same 
organism may not yield the same natural product.
21-23
Fortunately, recent advances in several related fields have helped to overcome 
many of the difficulties associated with natural products chemistry. Developments in 
synthesis methodology have relieved much of the supply problem; even natural 
products of enormous structural complexity are often rapidly synthesized. Issues of 
sample ‘dirtiness’ and slow compound isolation are being addressed by pre-treatment  
and prefractionation of crude samples prior to HTS, a process which will be discussed 
later in the chapter. At present, rediscovery of known compounds remains the major 
hurdle to efficient natural products discovery. In my thesis research, I took two very 
different approaches to this problem. The first involved looking for new natural 
products in a group of underexplored organisms – the fungi that live inside vascular 
plants, or endophytic fungi. The second approach focused on using new and specific 
bioassays to find new molecules (or known molecules with previously unknown 
activity), even among well-studied organisms – for example, traditional Chinese 
medicinal plants. 
 
Diving into the woods: exploiting biodiversity to find new chemical diversity 
Fungi are prolific producers of bioactive secondary metabolites, including 
molecules with diverse biological targets belonging to virtually every known class of 
natural products.
24 Classic examples illustrating the therapeutic and economic 
4 significance of fungal natural products include the antibiotic penicillin (a modified 
amino acid) from Penicillium chrysogenum (1), the immunosuppressant cyclosporine 
(a cyclic peptide) from Tolypocladium inflatum (2), and the cholesterol-lowering 
mevinolin (a polyketide) from Aspergillus terreus (3) (Figure 1.1). The mevinolin-
derived statin drug Zocor was the second bestselling drug in 2005, accounting for over 
$4 billion in annual sales,
25 and beta-lactams such as penicillin represent more than 
half of the antibiotic market. 
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Figure 1.1. Structures of selected natural products from fungi. 
Yet fungi represent a virtually untapped resource. The number of fungal 
species worldwide is estimated to be 1.5 million,
26 although many studies have 
suggested that this is a very conservative estimate.
27-29 Fewer than 5% of these fungal 
species have been described, and fewer than 1% are available in the world’s culture 
collections.
30 Studies of ecologically interesting fungi have yielded novel structures at 
unusually high rates, with previously unreported molecules accounting for 60-67% of 
the total that were isolated,
31 suggesting that the untapped biodiversity will yield lots 
of interesting chemical diversity. 
Endophytic fungi – literally, the fungi within plants – are predicted to be a 
deep reservoir of natural products. These fungi are ubiquitous in nature, with 
potentially hundreds of fungal species colonizing each individual plant species, 
including several that are unique to each plant.
32-34 Secondary metabolites are believed 
5 to be produced in response to stress and to mediate interactions with other organisms. 
Endophytes, which are in constant interaction with their plant hosts, other fungi, 
bacteria, and insects, prove to be especially prolific chemists.
32 Eighty percent of 
extracts from endophytic fungi show biological activity.
35 From the small fraction of 
endophytic fungal species that have been examined chemically so far, a plethora of 
chemically unique and biologically active natural products have been discovered.
36, 37 
Many endophytes are also culturable on traditional media, making it easy to obtain 
large amounts of any discovered metabolite by fermentation. 
In an effort to discover new bioactive natural products from endophytic fungi, 
the Clardy lab collected fungi from plants in the Archbold Biological Station (ABS) in 
Lake Placid, Florida and in the Guanacaste Conservation Area in Costa Rica. 
The Lake Wales Ridge (LWR) region of central Florida is a geographic oddity 
with an especially high concentration of endemic and endangered plant and animal 
species. This ancient scrub ecosystem was formed over a million years ago, as the 
ocean deposited sand on what was then an island. Unique plants and animals evolved 
in isolation until 20,000 years ago, when the last glacial stage caused the waters to 
recede. The unique landscape of the LWR includes southern ridge sandhills, sand pine 
scrubs, and scrubby flatwood, along with swale, bayhead, and seasonal ponds. Today, 
the 2400 km
2 LWR is a “hot spot” for threatened biodiversity,
38 containing 32 species 
classified as endangered or threatened by the US Fish and Wildlife Service and 44 
species classified as imperiled or vulnerable worldwide (G1, G2, or G3) by the Florida 
National Areas Inventory.
39 Formed in 1941 for the preservation and study of the 
LWR habitats,
40 the ABS contains an estimated 450-650 vascular plants,
41, 42 9% of 
which are endemic to Florida. Extrapolation from accepted estimates of endophytic 
fungal diversity gives a conservative estimate of 2700-3900 fungal species in the 
station. However, no studies of fungal diversity in the LWR region exist. 
6 Costa Rica boasts incredible topological, climatic and biological diversity. In 
an area of 51,000 km
2, Costa Rica contains active volcanoes, tropical rain forests, 
cloud forests, Pacific and Caribbean beaches, and desert-like dry areas.
43 Costa Rica 
also contains an estimated half million species, representing 4% of the total number of 
terrestrial species on earth.
44 In one study, 236 species of vascular plants were found 
in a 0.01 hectare plot in Costa Rica – approximately one hundred times as many plant 
species as found in the same size plot within temperate forests in the United States.
45 
Much of Costa Rica’s diversity is found within the Guanacaste Conservation Area, an 
1150 km
2 reserve on the Pacific coast of Costa Rica which is estimated to hold 
230,000 species, including 50,000 species of fungi.
46 A study of fungi from leaf litter 
in a Costa Rican rainforest yielded hundreds of species of fungi with a high proportion 
of rare species,
47 and similarly high levels of species diversity (and chemical diversity) 
are expected among our collection of Costa Rican endophytes. Some of the chemical 
diversity obtained by the Clardy Lab from endophytic fungi collected in the 
Guanacaste Conservation Area and ABS over the past decade is shown in Figure 1.2. 
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Figure 1.2. New chemistry obtained from endophytic fungi in the Clardy lab.
48-52
7 Organic extracts of endophytic fungi from the Guanacaste Conservation Area 
and from the ABS in Florida were screened against a variety of drug targets at Wyeth 
Research. The isolation and structure elucidation of phaeosphaeride A (4), a specific 
inhibitor of the cancer target STAT3, and its inactive diastereomer phaeosphaeride B 
from the Floridian fungal isolate FA39 is reported in Chapter 2. The isolation of a new 
family of dihydroxyhexanoic acid oligomers (5) (Figure 1.2) from the Costa Rican 
fungus CR873 is reported in Chapter 3. 
Having new eyes: using unique bioassays in the search for new natural products 
The vast majority of known natural products were found using a single 
bioassay, namely, a growth inhibition assay with assorted bacterial and fungal strains, 
or tumor cell lines. This assay is cheap and easy to perform, and has yielded a wide 
variety of antibiotic, antifungal, and anticancer natural products over the years. 
However, after decades of performing this same assay, it is no surprise that natural 
product rediscovery rates have climbed to the point where only one of every 500 ‘hits’ 
from this assay can be attributed to a new compound.
16
Only a minority of natural products have been broadly screened against a 
variety of targets.
53 Therefore, a change of search criteria to include new and 
interesting biological screens is likely to yield new molecules, even from previously 
studied organisms. This approach has an added advantage: even the rediscovery of a 
known molecule can represent an interesting result if the activity being studied is 
important, or the assay used to find it innovative. With this in mind, the Clardy lab 
began an extensive collaboration with the Institute of Chemistry and Cell Biology 
(ICCB-Longwood) at Harvard Medical School, an investigator-initiated screening 
facility that allows academic investigators access to a library of 3700 natural product 
8 extracts for use in their screens. Results from three of these collaborative screening 
projects are described in Chapters 4 and 5; each is introduced briefly below. 
In collaboration with Ulrike Eggert and Tim Mitchison of the Department of 
Systems Biology at HMS, crude plant extracts from the National Cancer Institute were 
screened for cytokinesis inhibitory activity. Cells were exposed to the extracts and 
stained to visualize the cytoplasm and DNA, and binucleate cells (cells that had 
undergone DNA replication, but whose cytoplasm had not divided) were imaged using 
automated fluorescence microscopy (Figure 1.3a). The isolation and structure 
elucidation of two new cytokinesis-inhibitory cucurbitacins from the conifer 
Physocarpus capitatus and studies to determine their cellular target are described in 
Chapter 4.  
For reasons mentioned previously, screening of crude natural product extracts 
is far from ideal. As a result, many industrial natural products labs have shifted to 
screening prefractionated or pure natural product libraries in order to compete with 
combinatorial libraries,
54-56 and their initial results are encouraging: purified natural 
products have shown superior hit-rates to synthetic libraries in five out of nine assays, 
with similar or better confirmation rates.
57 Through a long-standing collaboration with 
researchers at the National Biodiversity Institute (INBio) in Costa Rica, the Clardy lab 
obtained access to technology that enables large-scale prefractionation of natural 
product extracts. In an initial project funded by the Starr foundation, a collection of 50 
traditional Chinese medicinal plants was prefractionated in Costa Rica and fractions of 
sufficient size were sent to the ICCB-Longwood to be used in investigator-initiated 
screens. 
The Starr extracts were screened for activators of TRPV4, a member of the 
vanilloid family of transient receptor potential channels, in collaboration with Paula 
Smith and David Clapham of the Children’s Hospital in Boston. Hits from the primary 
9 assay, which employed a fluorescent calcium indicator, were subjected to 
electrophysiology measurements (Figure 1.3b). Fractions from several traditional 
Chinese medicinal plants showed activity in both assays. The isolation and structure 
elucidation of bisandrographolide A from Andrographis sp. (chuan xin lian); structure 
elucidation of kaikasaponin III from Sophora sp. (shan dou gen); and the identification 
of linoleic acid as the active component from Stellaria sp. (yin chai hu), and Fritillaria 
sp. (chuan bei mu) are described in Chapter 5, along with details of the assays. 
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Figure 1.3. Screens of natural product extracts at the ICCB-Longwood. 
In collaboration with Pete Bayliss and Tom Roberts of the Dana Farber Cancer 
Institute, the Starr extracts were screened for angiogenesis inhibitors. This medium-
throughput screen employed transgenic Tg(Fli1-GFP) zebrafish embryos with 
fluorescent blood vessels which allowed facile visualization of blood vessel 
development (Figure 1.3c). A fraction from Stellaria sp. (yin chai hu) caused severe 
vascular abnormalities, pericardial edema, and dorsal curvature in the zebrafish 
embryos at a concentration of less than 100 μM. The structure elucidation of 
10 hydroferulic acid and subsequent optimization of its activity are also described in 
Chapter 5. 
These results demonstrate that biodiversity prospecting and broad screening of 
natural product extracts are complementary strategies for discovering bioactive natural 
products. These approaches yielded not only the original object, that is, new 
biologically active molecules, but also several surprises, including a new family of 
non-templated biopolyesters (the first produced by a eukaryote), and some remarkably 
simple chemical structures that cause never-before-observed phenotypes. These 
studies also suggest that the newest efforts in the Clardy lab, involving the broad 
screening of prefractionated fungal extracts at the ICCB-Longwood, will reveal even 
greater levels of novel chemical diversity.
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16 Chapter Two 
Phaeosphaeride A, an Inhibitor of STAT3-Dependent Signaling  
Isolated from an Endophytic Fungus
∗
 
 
Signal transducer and activator of transcription (STAT) 3 plays a vital role in 
regulating cell growth and survival. In response to growth factor and cytokine 
stimulation, STAT3 becomes phosphorylated, dimerizes, and translocates into the 
nucleus to up-regulate transcription of a wide spectrum of genes. In many cancers – 
including breast,
1 prostate,
2 ovarian,
3 and skin
4 – constitutively activated STAT3 
inappropriately upregulates genes that promote angiogenesis
5 and prevent apoptosis
6 
A constitutively active mutant STAT3 is sufficient to cause cell transformation and 
tumor formation.
7 
The short STAT3 pathway offers few opportunities for small molecule 
therapeutic intervention. The natural products cucurbitacin I (1) and resveratrol (2) 
both inhibit STAT3 activity by targeting tyrosine kinase activators,
8, 9 and the 
semisynthetic flavone flavopiridol (3) interferes with STAT3 binding to DNA.
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Figure 2.1. Selected inhibitors of STAT3 signaling. 
                                                 
∗ Reproduced in part with permission from: Maloney, K.N.; Hao, W.; Xu, J.; Gibbons, J.; Hucul, J.; 
Roll, D.; Brady, S. F.; Schroeder, F. C.; Clardy, J. Organic Letters 2006, 8, (18), 4067-4070. Copyright 
[2006] American Chemical Society. 
17 Flavopiridol is in phase I clinical cancer trials, but in addition to disrupting 
STAT3-DNA binding, flavopiridol also inhibits several growth promoting kinases.
11 
In an effort to identify other small molecule inhibitors of STAT3, a 10,000-member 
library consisting primarily of natural product extracts was screened for the ability to 
disrupt STAT3-DNA binding. Active molecules were detected by adding test samples 
to cell lysate containing activated STAT3 and incubating in oligonucleotide-coated 
wells displaying the STAT3-binding sequence. Extracts that inhibited STAT3-DNA 
binding were detected by ELISA using a STAT3-specific primary antibody and 
horseradish-peroxidase-linked secondary antibody.  This chapter reports the isolation 
of phaeosphaeride A (4), a selective inhibitor, and its inactive diastereomer 
phaeosphaeride B (5). 
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Figure 2.2. Structures (including relative stereochemistry) of the phaeosphaerides.
∗
Endophytic fungi were isolated from plant samples collected in the Archbold 
Biological Station, a five-thousand-acre preserve in Lake Placid, Florida, which is 
home to an exceptionally high concentration of endemic and endangered plant species 
representing the distinct evolutionary history of the Florida highlands.
12, 13 In order to 
identify STAT3 inhibitors, organic extracts of fungal cultures were added to cell 
lysate. 
                                                 
∗ Numbering used is the same as for the spirostaphylotrichins. (See reference 16.) 
18 Endophyte FA39 showed uniquely potent activity against STAT3. FA39 was 
identified by rDNA sequence as having 97% identity to the ascomycete 
Phaeosphaeria avenaria, the causative agent for a blotch disease of cereals. In an 
effort to maximize production of STAT3 inhibitory activity, FA39 was grown under a 
variety of conditions. Interestingly, only the extracts from cultures grown on a 
breakfast cereal showed activity against STAT3.  
In order to purify the STAT3 inhibitory compounds, fungal material was 
extracted exhaustively with methanol, and the extract clarified by centrifugation prior 
to evaporation in vacuo. Isolation began with solvent partitioning. The extract was 
redissolved in 90% aqueous methanol and defatted with hexanes. The methanolic 
fraction was then adjusted to 60% aqueous methanol and partitioned with 
dichloromethane. The dichloromethane fraction was chromatographed on silica gel 
(50:1 dichloromethane/methanol eluent), and reversed-phase HPLC (65% aqueous 
acetonitrile eluent) to give pure phaeosphaeride A (4). 
Phaeosphaeride A (4) was obtained as an optically active ([α]
25
D -93.6 (c 2.0, 
CH2Cl2)) yellow glass. HRESIMS revealed an [M+1]
+ ion with exact mass 298.1656, 
corresponding to the molecular formula C15H23NO5 + H (calcd 298.1654), and five 
degrees of unsaturation. The 
13C NMR spectrum of 4 displayed 15 carbon resonances, 
consistent with the HRMS data. Comparison of the 
13C NMR and DEPT spectra of 4 
revealed five quaternary carbons, two methine carbons, five methylene carbons, and 
three methyl carbons. Attached protons for each carbon were established by 
1H-
13C 
HMQC. 
Three spin systems were observed in the double quantum-filtered 
1H-
1H COSY 
(dqfCOSY) spectrum of 4 in DMSO-d6 (Figure 2.3a). One spin system extended from 
the methyl protons at δ 0.85 (H-13) through four sets of methylene protons (δ 1.28, H-
12; 1.27, H-11; 1.44, H-10; 1.51 and 1.82, H-9) to the methine proton at δ 4.07 (H-8), 
19 corresponding to a straight six-carbon chain. A second spin system consisted of the 
two protons of a terminal alkene (δ 4.96 and 4.97, J = 1.8 Hz, H-14). In the remaining 
spin system, a proton at δ 3.86 (H-6) coupled to a proton signal at δ 5.44 (OH-6, J = 
5.3 Hz). The latter signal was not observed in the 
1H NMR spectrum taken in CD3OD, 
indicating an exchangeable proton. 
O
N
O
HO
OH
OCH3
NOESY HMBC
1
3
4
5
6 8
14
15
16
O
HO
OH
O
H
H
a b c
OH
6 8
7
15
14
Figure 2.3. (a) Spin systems observed in the dqfCOSY spectrum of phaeosphaeride A 
(4). (b) Important HMBC correlations for 4. (c) Important NOEs for 4. 
Correlations seen in the 
1H-
13C HMBC spectrum of 4 established the carbon 
skeleton shown in Figure 2.3b. Methyl protons at δ 1.18 (H-15) and an exchangeable 
proton at δ 4.92 (OH-7) both showed strong correlations to methine carbons at δ 64.1 
(C-6), and 86.2 (C-8), and to the quaternary carbon at δ 70.8 (C-7), thus establishing 
the connectivity of carbons C-6 through C-8, and the methyl and hydroxyl groups 
attached to C-7. The methine proton at δ 3.86 (H-6) showed 
1H-
13C HMBC 
correlations to carbons at δ 104.7 (C-5), 155.2 (C-4), and 166.5 (C-1), in addition to 
(redundant) correlations to carbons C-7 and C-8 (δ 70.8 and 86.2, respectively). No 
other proton resonances showed correlations to C-1 (δ 166.5). The terminal alkene 
protons (δ 4.96 and 4.97, H-14) showed strong correlations to the carbon at δ 155.2 
(C-4) and to a carbon at δ 137.0 (C-3). C-3 can only be located between C-14 and C-4. 
An observed correlation from the methine proton H-8 (δ 4.07) to C-4 (δ 155.2) can 
20 only be explained if carbons C-4 through C-8 are arranged in a ring. The chemical 
shifts of C-4 (δ 155.2) and C-8 (δ 86.2) indicate they are connected by oxygen. 
Of the five degrees of unsaturation allowed by the molecular formula, four are 
accounted for by the ring (connecting carbons C-4 through C-8), two double bonds 
(connecting C-4 to C-5 and C-3 to C-14), and a carbonyl group at C-1 (δ 166.5). Only 
a methyl group and one atom each of nitrogen and oxygen remain from the molecular 
formula. The remaining methyl group is very highly deshielded, with a carbon 
chemical shift of δ 63.7 and proton shift of δ 3.79 (H-16), and hence must be attached 
to oxygen. The structure shown as 4 is the only structure consistent with all the NMR 
data and with the molecular formula determined by HRMS. 
The phase-sensitive NOESY spectrum of 4 showed a strong correlation 
between the deshielded methyl protons at δ 3.79 (H-16) and the terminal alkene proton 
at δ 4.96 (H-14), confirming the placement of this methyl group (Figure 2.3c). The 
NOE data are most consistent with the relative stereochemistry shown in Figure 2.3c. 
An NOE correlation between methine protons H-6 (δ 3.86) and H-8 (δ 4.07) establish 
the pseudodiaxial relationship of these hydrogens. Strong positive NOE correlations 
between both of these hydrogens and methyl protons H-15 (δ 1.18); as well as 
between the two OH protons (δ 5.44, OH-6; and 4.92, OH-7) suggest that both 
hydroxyls and the C-8 alkyl chain are on the same face. 
To confirm the configuration at C-7, p-bromobenzoyl derivatives of 
phaeosphaeride A (4) were prepared.  The major product was determined by NMR to 
be the mono-p-bromobenzoyl derivative of phaeosphaeride A (6). A second, minor 
product was demonstrated to be the tri-p-bromobenzoyl derivative (7) (Figure 2.4, 
Table 2.1). Attempts to crystallize 6 and 7 were unsuccessful. However, NOE spectra 
for each compound in DMSO-d6 provided additional evidence for the relative 
stereochemistry shown. NOE correlations between the methyl H-15 protons (δ 1.20 in 
21 6; 1.21 in 7) and both pseudodiaxial protons H-6 and H-8 (δ 5.78 and 4.31 in 6, 
respectively; 5.75 and 4.16 in 7) were stronger in 6 and 7 than in 4; presumably, the 
additional steric bulk provided by the bromobenzoyl substitutions enforces a more 
defined pseudochair conformation in the six-member ring. 
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Figure 2.4. p-Bromobenzoyl derivatives of phaeosphaeride A. 
Examination of the 
1H NMR spectra of the inactive fractions from FA39 
revealed a relative of phaeosphaeride A that eluted earlier from the silica column (20:1 
dichloromethane/methanol eluent). This compound was also purified by reversed-
phase HPLC (70% aqueous acetonitrile eluent) to give pure phaeosphaeride B (5). 
Phaeosphaeride B (5) was obtained as an optically active ([α]
25
D -157.2 (c 2.0, 
CH2Cl2)) orange glass. HRESIMS revealed an [M+1]
+ ion with exact mass 298.1660, 
which is consistent with a molecular formula of C15H23NO5 + H (calcd 298.1654), the 
same molecular formula as phaeosphaeride A (4). 
1H and 
13C NMR spectra of 5 were 
nearly identical to those for 4. The only significant differences were the carbon 
chemical shift at C-8 (δ 80.3 in 5, compared to 86.2 in 4); and the carbon and proton 
chemical shifts of the methyl group C-15 (δ 17.9 and 0.88 in 5, respectively; 20.5 and 
1.18 in 4). The NOESY spectrum of 5 lacked the diaxial correlation between the 
methine protons H-6 and H-8, indicating that 5 is a diastereomer of 4, differing in the 
stereochemical configuration at C-8.  
 
22 Table 2.1. Chemical shift assignments for 6 and 7 in CD2Cl2.  
   6  7 
 
  13C 
1H 
  13C 
1H 
1  164.44 -   165.89 - 
3  136.56 -   89.98  - 
4  158.35 -   166.13 - 
5  101.18 -   103.10 - 
6  71.53  5.745   71.0*  5.783 
7  71.19  -   71.00  - 
8  86.48  4.161   89.17  4.305 
9  27.86  1.838   27.9*  1.618,  1.777 
10  26.20  1.473,  1.661  26.48  1.323,  1.453 
11  31.59  1.367   31.16  1.086,  1.206 
12  22.69  1.363   22.50  1.189 
13  14.02  0.924   13.89  0.801 
14  92.03  5.037,  5.093  59.69  4.842,  4.914 
15  17.43  1.212   18.67  1.197 
16  64.60  3.889   66.27  3.819 
1’  -  -   163.31 - 
2’  -  -   127.23 - 
3’  -  -   131.81 7.948 
4’  -  -   132.41 7.686 
5’  -  -   129.80 - 
1’’  166.79 -   164.02 - 
2’’  128.59 -   127.70 - 
3’’  131.77 7.939   131.21 7.705 
4’’  132.11 7.635   132.24 7.280 
5’’  128.83 -   128.87 - 
1’’’  -  -   168.00 - 
2’’’  -  -   128.40 - 
3’’’  -  -   131.47 7.665 
4’’’  -  -   132.24 7.561 
5’’’  -  -   129.11 - 
          
* Obscured by overlap with other signals. 
 
The phaeosphaerides are related to several families of fungal metabolites, most 
notably the curvupallides, e.g. curvupallide A (8) isolated from Curvularia 
pallescens
14 and the lipid-lowering spirostaphylotrichins/triticones, e.g. 
spirostaphylotrichin A/triticone C (9) (Figure 2.5) isolated independently from 
Staphylotrichum coccosporum
15, 16 and from Drechslera tritici-repentis.
17, 18 These 
23 families of compounds share the unusual O-methyl hydroxamic acid functional group 
of the phaeosphaerides. However, the phaeosphaerides have a previously unreported 
methyl group at C-15. 
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Figure 2.5. Fungal metabolites related to the phaeosphaerides. 
As FA39 only produced the phaeosphaerides when grown on Fiber One cereal, 
it was not possible to do feeding studies to determine the biogenetic origins of 4 and 5. 
However, feeding studies performed by Sandmeier and Tamm on spirostaphylotrichin 
A/triticone C (9) showed that the molecule had a mixed origin, with ten carbons 
(corresponding to C-1 and C-5 through C-13 of 4) coming from a polyketide pathway, 
and three carbons (corresponding to C-3, C-4 and C-14 of 4) coming from aspartate. 
The O-methyl (corresponding to C-16 of 4) was shown to originate from methionine 
Figure 2.6. Biogenetic hypothesis for 
spirostaphylo r
(Figure 2.6).
16
the phaeosphaerides based on feeding studies of 
t ichin A/triticone C (9). 
50 of 0.61 mM in the primary 
ELISA-based screen. However, when tested in vivo using STAT3-dependent U266 
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Figure 2.8. Phaeosphaeride A (4) selectively inhibits STAT3. Data shown are from 
ELISA using whole-cell lysates of the indicated cancer cell lines. 
e myeloma cells, phaeosphaeride A (4) was almost 100-fold more potent, 
inhibiting cell growth with an IC50 of 6.7 μM, suggesting that 4 may have another 
target in cells. An additional target for 4 was also suggested by its low micromola
activity against the STAT3-independent K562 cell line (Figure 2.7). 
Figure 2.7. Phaeosphaeride A (4) inhibits growth of the STAT3-independent K562 
cell line (dashed line), suggesting a second target for STAT3 in cells. (Solid lines 
show cell growth of STAT3-dependent U266 cells.) 
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only slight activity against STAT1 from U937 cells and no activity against STAT5 
b2 cells in the ELISA-based assay (Figure 2.8). 
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25 Phaeosphaeride A (4) was also active against STAT3 from a second cancer c
line (HepG2). Interestingly, its diastereomer phaeosphae
ell 
ride B (5) showed no activity 
nonspecific reactivity toward Michael addition (Figure 2.9). 
Figure 2.9.  
tic 
fungi.
19-21
 
INOVA 500 MHz spectrometer equipped with a cryoprobe. Offline processing 
as conducted using Mestre-C NMR Software (Mestrelab Research, A Coruña, Spain; 
m). 
1H and 
13C chemical shifts of 4 and 5 were referenced with the 
against STAT3, suggesting that the activity of 4 cannot be explained merely by 
 Phaeosphaeride B (5) is inactive against STAT3. Data shown are from
ELISA using whole-cell lysates with U266 cells. 
We have identified two fungal metabolites based on a new carbon skeleton, 
one of which is a selective inhibitor of the cancer target STAT3. The phaeosphaerides 
join the growing number of pharmaceutically useful natural products from endophy
Experimental: 
General Experimental Procedures: All NMR spectra were measured using a Varian 
Unity 
w
www.mestrec.co
DMSO solvent peaks at δ 2.50 and δ 39.4, respectively; chemical shifts of 6 and 7 
were referenced with the dichloromethane solvent peaks at δ 5.32 and δ 53.8. IR 
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26 spectra were recorded on a Mattson Galaxy Series 3000 FTIR spectrometer. Optical 
rotation data were obtained using a Jasco DIP-370 polarimeter. High resolution mass 
spectra were run by the University of Illinois Mass Spectrometry facility. HPLC w
carried out on an Agilent 1100 system equipped with diode array detector and 
operated with Chemstation software (Agilent Technologies). All HPLC separations 
were done using a Discovery HS-C18 column (Supelco, 250 x 10.0 mm, 5mm particle
size) with a 4mL/min flow rate. Column chromatography was carried out on sil
60 (FisherChemicals, 230-400 mesh). 
 
Fungal material: FA39 was isolated from the interior of a plant harvested from the 
Archbold Biological Station in Florida.
as 
 
ica gel 
 Plant tissue was surface sterilized by 
ccessive 5-minute washes in 10% bleach, 70% ethanol, and three fresh portions of 
cultured 
ng 
t (Promega Corporation, Madison, WI) 
nd used in a Polymerase Chain Reaction with primers LR0R (5’-
ed in a BLAST 
su
sterile water. Five-mm squares of plant tissue were cut from the surface-sterilized 
specimen and placed on PDA plates to promote fungal growth. FA39 was sub
from the fungi that grew from these samples after two days and then successively 
subcultured to obtain a pure fungal culture. 
 
FA39 rDNA Sequencing: Genomic DNA was extracted from the fungal tissue usi
the Wizard® Genomic DNA Purification Ki
a
ACCCGCTGAACTTAAGC-3’) and LR5 (5’-TCCTGAGGGAAACTTCG-3’) to 
amplify a 900 base pair fragment of the large subunit ribosomal DNA. The PCR 
product was cloned and sequenced, and the consensus sequence us
search to identify closely related fungi. 
 
27 Culture Conditions: Culture conditions tested included stationary and shaken 
cultures in potato dextrose broth and rich/poor culture conditions (a carbon-rich seed 
llowed by carbon-poor production medium), as well as culturing on solid media 
tions 
 
ne 
opylethylamine, 4 equivalents of p-
romobenzoyl chloride, and a catalytic amount of (dimethylamino)pyridine. The 
merica, Carlsbad, CA), 
ccording to manufacturer instructions. 
elded 
 506 mg active dichloromethane extract. Silica 
el chromatography gave 45.4 mg of crude phaeosphaeride A and 25.5 mg crude 
fo
including cracked corn, rice, and Fiber One cereal. The optimized culture condi
were as follows. Agar plugs of FA39 were used to inoculate seed cultures in potato 
dextrose broth at 25 ºC. The three-day old seed cultures were then used to inoculate
flasks containing Fiber One cereal that had been wetted with 0.1% yeast extract. The 
fungus was allowed to grow for seven days at 25 ºC prior to extraction. A control 
extract of Fiber One cereal was inactive. 
 
Preparation of p-Bromobenzoyl Derivatives: Dry 4 was stirred in dichlorometha
on ice with 4.5 equivalents of N,N-diisopr
b
reaction was allowed to slowly warm to room temperature and was stirred until 
complete disappearance of 4, as observed by LCMS. 
 
STAT Inhibition Assay: The assay was performed using the Trans-AM STAT 
Transcription Factor Assay Kit (Active Motif North A
a
 
Isolation. Methanol extraction of FA39 growing on 32.4 g Fiber One cereal yi
2.35 g extract. Solvent partitioning gave
g
phaeosphaeride B. HPLC purification of phaeosphaeride A yielded 32.8 mg pure 
compound. 
 
28 Phaeosphaeride A (4)  was obtained as an optically active yellow glass, [α]
25
D -93
(c 2.0, CH
.6 
l2); UV λmax (CH3CN) 262 nm; IR (NaCl, thin film) νmax: 3421, 2956, 
931, 2860, 1706, 1633, 1445, 1087, 1064 cm
-1; 
13C NMR (DMSO-d6, δ): 166.5 (C-
-
 
 
2 
 (NaCl, thin film) νmax: 3387, 1955, 
932, 2859, 1701, 1637, 1444, 1058, 1012 cm
-1; 
13C NMR (DMSO-d6, δ): 165.3 (C-
 
, 
2C
2
1), 155.2 (C-4), 137.0 (C-3), 104.7 (C-5), 90.8 (C-14), 86.2 (C-8), 70.8 (C-7), 64.1 (C
6), 63.7 (C-16), 30.8 (C-11), 27.5 (C-9), 25.9 (C-10), 21.9 (C-12), 20.5 (C-15), 13.8
(C-13); 
1H NMR (500 MHz, DMSO-d6, δ): 5.44 (d, J = 5.5 Hz, 1H, OH-6), 4.97 (d, J
= 1.8 Hz, 1H, H-14a), 4.96 (d, J = 1.8 Hz, 1H, H-14b), 4.92 (s, 1H, OH-7), 4.07 (d, J = 
11.5 Hz, 1H, H-8), 3.86 (d, J = 5.5 Hz, 1H, H-6), 3.79 (s, 3H, H-16), 1.82 (m, 1H, H-
9a), 1.51 (m, 1H, H-9b), 1.44 (m, 2H, H-10), 1.28 (m, 2H, H-12), 1.27 (m, 2H, H-11), 
1.18 (s, 3H, H-15), 0.85 (t, J = 6.7, 3H, H-13). HRESIMS (m/z): [M + 1]
+ calcd for 
C15H23NO5 + H, 298.1654; found, 298.1656. 
 
Phaeosphaeride B (5) was obtained as an optically active orange glass, [α]
25
D -157.
(c 2.0, CH2Cl2); UV λmax (CH3CN) 262 nm; IR
2
1), 156.8 (C-4), 136.0 (C-3), 105.0 (C-5), 91.4 (C-14), 80.3 (C-8), 69.4 (C-7), 63.6 (C-
6), 63.4 (C-16), 30.8 (C-11), 26.6 (C-9), 25.1 (C-10), 21.6 (C-12), 17.9 (C-15), 13.7
(C-13); 
1H NMR (500 MHz, DMSO-d6, δ): 5.49 (d, J = 5.9, 1H, OH-6), 5.03 (d, J = 
2.0, 1H, H-14a), 5.02 (d, J = 2.0, 1H, H-14b), 4.59 (s, 1H, OH-7), 3.98 (dd, J = 10.6 
Hz, J = 1.8 Hz, 1H, H-8), 3.78 (s, 3H, H-16), 3.75 (d, J = 5.9 Hz, 1H, H-6), 1.86 (m, 
1H, H-9a), 1.63 (m, 2H, H-10), 1.54 (m, 1H, H-9b), 1.33 (m, 2H, H-12), 1.32 (m, 2H
H-11), 0.90 (m, 3H, H-13), 0.88 (s, 3H, H-15); HRESIMS (m/z): [M + 1]
+ calcd for 
C15H23NO5 + H, 298.1654; found, 298.1660. 
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Chapter Three 
Poly(3,5-Dihydroxyhexanoic Acid) Isolated from a Costa Rican Fungus 
 
 
While template-dependent polymer biosynthesis is a hallmark of all life, 
plate-dependent polymer biosynthesis is an idiosyncratic phenomenon. The 
hesis of polyhydroxybutyr
nontem
biosynt ate (poly(3-HB)), the polyester of 3-
depend thesis as shown in Figure 3.1. Poly(3-HB) forms under 
conditions, glucose is converted to acety
s.
1 The 
poorly 
eight.  When conditions become more favorable, poly(3-HB) can be hydrolyzed to 
3-HB, w way at the 3-hydroxy stage, to 
energy 
when nutrient limitations are lifted. 
Figure
comme ble, biocompatible polymers.
3-5 However the 
incorporating new monomers with unique properties are desired.
6 At this time some 
HO
hydroxybutanoate (3-HB), by bacteria has become a paradigm for nontemplate-
ent polymer biosyn
nutrient-limited growth conditions with an ample carbon source. Under these 
l-CoA, which in turn is converted to 3-HB-
CoA and poly(3-HB) by a series of relatively well-characterized enzyme step
soluble poly(3-HB) forms granules that can constitute up to 80% of the dry cell 
2 w
hich enters the fatty acid β-oxidation path
generate energy and reducing equivalents. By this strategy bacteria obtain (limited) 
from the carbon source and stockpile a material that can be utilized readily 
 3.1. Biosynthesis and utilization of poly(3-HB) by bacteria. 
Poly(3-HB) and other polyhydroxyalkanoic acids (PHAs) have received much 
rcial interest as biodegrada
homopolymer of poly(3-HB) is unsuitable for most applications and PHAs 
O O OH
O O O
n HO SCoA
O O β-oxidation
pathway
carbon
source
SCoA
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150 different hydroxyacid monome rved in bacterial PHAs,
7, 8 the 
vast ma  
membrane-associated poly(3-HB) (minute amounts of which are present in all 
organisms)
9 and poly(malic acid),
10, 11 PHAs have been observed exclusively in 
prokary
 
is polymer, 
ws an 
 
odiversity, including an estimated 64,000 
l kinase in the 
NFκB signaling pathway. While attempting to identify the source of the activity 
against
dance 
rs have been obse
jority of which are esterified at a 3-hydroxy group. With the exception of
otes. 
We report an endophytic fungus from Costa Rica that excretes large amounts
of poly((3R,5R)-3,5-dihydroxyhexanoic acid) (poly(3,5-DHH)) (1). Th
which contains a monomer not previously reported as a component of PHAs, sho
interesting pattern of connectivity at the hydroxy end which suggests an interesting
biosynthetic route. 
Figure 3.2. Poly(3,5-dihydroxyhexanoic acid) from CR873. 
As part of a recent study, endophytic fungi were isolated from tissue samples 
of 65 plants collected in the Guanacaste Conservation Area of Costa Rica, a country 
containing some 4 % of the world’s bi
HO O O O OH
OH O O OH O O OH
OH
n
1
undescribed fungi.
12 Extracts of the 686 fungal isolates obtained were screened against 
a number of important drug targets. The lysate of one fungus, CR873, isolated from 
Manilkara sp., showed strong inhibition of IκB kinase (IKK) – a vita
 IKK, we observed a number of dihydroxyhexanoic acid derivatives which, 
although themselves inactive in the assay, caught our attention due to their abun
in the extract. 
33  
CR873 was identified by rDNA sequence as having 99% identity to the 
ascomycete Daldinia concentrica. A liquid culture of CR873 grown in potato dext
broth was subjected to solid-phase extraction using Diaion HP-20 resin (yield 0
extract/L culture). This organic extract was then subjected to size-exclusion 
chromatograp
rose 
.269 g 
hy on Sephadex LH-20 (methanol eluent). Poly(3,5-dihydroxyhexanoic 
acid) (1
)HCH2-. Corresponding 
13C shifts were determined by HMQC, 
and both 
1H and 
13
atoms. HM A; 2.42, 2.51 
in B; 2.62, 2.69 in  δ 175.7 in A, 
172.4 in B, 171.5 in  of a carbonyl adjacent 
etween H-5 (δ 5.10) and 
C-1 (δ 172.4) of 
 units are present in only minor amounts. The precise ratio between 
major B unit and minor A, C, and D units varies between the different fractions from 
) was obtained as the first twenty fractions from the column, accounting for 
29% of the total organic extract. 
1H NMR and 
1H–
1H double quantum filtered COSY (dqfCOSY) spectra of 1 
revealed four related units, A, B, C, and D with a common spin system, 
CH3C(X)HCH2C(Y
C chemical shift data were consistent with X and Y being oxygen 
BC cross-peaks from methylene protons H-2 (δ 2.39, 2.48 in 
C; and 2.42, 2.50 in D) to their respective carbon C-1 (
C, and 172.7 in D) indicated the presence 
to the C-2 methylene in each system. An HMBC cross-peak b
B suggested an ester linkage from one B unit to another B unit. An 
HMBC cross-peak from H-3 of C (δ 5.38) to C-1 of D (δ 172.7) suggested an ester 
linkage connecting C to D. Neither of the methine protons of D showed HMBC 
crosspeaks to suggest another ester linkage, and the chemical shift values for H-3 (δ 
4.16) and H-5 (δ 3.94) are consistent with free hydroxyls at those positions in D. 
Chemical shifts of A were virtually identical to those of B, with the exception of the 
13C chemical shift of carbon C-1 (δ 175.7), which is consistent with a free acid at that 
position. 
1H NMR peak integration indicated that B is by far the major component, and 
that A, C and D
34  
the Sep Taken 
ol 
tion is that the biosynthetic machinery utilizes a 3-
OH-lin
ions at the 
 
 
(1
 of dihydroxyhexanoic acid ranging in size from a pentamer up to a 27-mer. 
As expe
1)
-  
hadex column, with earlier fractions containing a larger proportion of B. 
together, these observations suggest that the molecules are oligomers of 
dihydroxyhexanoic acid. A is the carboxylic acid terminus, while B appears to be the 
main repeating unit. D, which has no further ester bonds, appears to be the di
terminus. Interestingly, the 3-OH-linked C unit is always observed between a 5-OH-
linked B unit and the terminal D unit (giving the (1,3) terminal linkage shown in 
Figure 3.3). One possible explana
ked dihydroxyhexanoic acid dimer as a handle for priming poly(3,5-DHH) 
biosynthesis with extension occurring by way of 5-OH-linked esterificat
carboxylic acid (A) end of the growing polymer. This variation in esterification site 
has not been reported in other PHAs. However, neither poly(3-HB) nor any of the 
other well-documented PHAs have structures that afford the option of a distinct starter
unit. 
Figure 3.3. General structure of poly(3,5-dihydroxyhexanoic acid). Spin systems from 
the dqfCOSY spectrum and selected HMBC correlations are shown. 
Negative ion mass spectra of the polymer-containing Sephadex fractions 
revealed a large number of molecular ions (M-1)
-, which adhered to the formula M =
30 × m) + 18, where m = 5, 6, 7,…, 27. These masses are consistent with linear 
oligomers
(1,3) (1,5) (1,5)
HO O O O OH
OH O O OH O O OH
OH
n
A B C D
dqfCOSY
HMBC
1
cted, higher molecular weight oligomers eluted earlier from the Sephadex 
column. For example, the largest peak in the mass spectrum of Fraction 10 is at (M-
35  
2357, corresponding to a linear 18-mer, while the largest peak in the mass spectrum of 
Fraction 15 is at (M-1)
- 927, corresponding to a 7-mer (Figure 3.4). 
Figure 3.4. Negative-ion ESI mass spectra of two fractions from a size-exclusion 
In order to confirm that the oligomers were not simply artifacts generated by 
the m
Katherine, fraction 10 oligomers ESI-, higher resolution, cone voltage (83), with ammonia, lower masses
900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400
m/ z 0
100
%
Katherine, fraction 15 oligomers ESI-, higher resolution, cone voltage (54), with conc. ammonia, lower masses
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2098 
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2488 
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1968 
column of poly(3,5-DHH). 
ass spectrometer, LC-MS of several of the Sephadex fractions was performed. 
Figure 3.5. Negative-ion ESIMS total ion chromatogram of Sephadex fraction 15 
While the separation of the oligomers on C18 was not sufficient to show individual 
km-f15-100mg/ml
containing a mixture of oligomers (top), and chromatograms of selected ions 
corresponding to individual oligomers. 
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peaks in the total ion chromatogram, comparison of the traces of different ions 
revealed sequential elution of individual oligomers, with longer oligomers showing a 
er 3,5-
dihydroxyhexanoic acid (2), which cyclized to form the δ-lactone (3) upon 
acidification and subsequent lyophilization. Lactone 3 was purified by silica gel 
chromatography (5:1 ethyl acetate/hexanes eluent). Analysis of the coupling constants 
observed in the 
1H NMR spectrum of 3 in CDCl3 revealed the anti-relationship shown 
in Figure 3.6. The strong coupling (J = 11.3 Hz) between H-4ax (δ 1.74) and H-5 (δ 
er 
coupling (J = 3.3 Hz) between H-4ax (δ 1.74) and H-3 (δ 4.39) indicates a 
pseudo
Figure 3.6. R) δ-
lacton
e 
slightly longer retention time on the C18 column (Figure 3.5). 
Hydrolysis of poly(3,5-DHH) under basic conditions gave the monom
4.85) indicated that both these protons are in pseudoaxial positions, while the weak
equatorial H-3. A comparison of the optical rotation of 3 ([α]
25
D +26.2 (c 0.2, 
CHCl3)) with literature values
∗ confirmed the absolute stereochemistry shown in 
Figure 3.6.
13, 14
OH
 Hydrolysis of poly(3,5-DHH) followed by cyclization gave the (3R,5
e (3). 
We believe that poly(3,5-DHH) fulfills a role similar to that suggested for 
poly(3-HB) in bacteria: a temporary storage of reduced carbon in a form that can b
                                                 
∗ (a) [α]
25
D +23.1 (c 1.0, CHCl3) synthesized by Bennett et al. (See reference 13.); (b) [α]
25
D +30.1 (c 
1.3, CHCl3) synthesized by Le Sann et al. (See reference 14.) 
HO O O O OH
OH O O OH O O OH
n
O
O
HO
3
2
KOH
HCl
H2O
HO OH
OH O
1
35
37  
easily oxidized later. Both poly(3,5-DHH) and poly(3-HB) come from acetyl-Co
is intercepted before it enters the citric acid cycle. However, while poly(3-HB) is 
typically sequestered inside the bacterial cell as insoluble granules, poly(3,5-DHH) is 
A that 
excrete . 
n an as-
 
 
orage 
ers 
that are produced in large quantities by the ascomycete CR873. This is the first report 
eter.
 1H and 
13C chemical shifts of 1 were referenced with the 
referenced with the chloroform solvent peaks at δ 7.26 and δ 77.0. IR spectra were 
recorded on a Mattson Galaxy Series 3000 FTIR spectrometer. Optical rotation data 
were obtained using a Jasco DIP-370 polarimeter. Low resolution mass spectra were 
d from the cell as relatively low molecular weight and water soluble polymers
The fungus feeds on this extracellular carbon source by excreting enzymes o
needed basis. This phenomenon could also reflect a resource competition strategy
whereby some organisms utilize fermentation (high consumption rate, low ATP 
production) to out-compete those organisms using respiration (low consumption rate, 
high ATP production) for resources.
15-17 Since the end product of fermentation is 
stored in a form inaccessible to the members using respiration, in this case a polyester,
the fermenters can eliminate respirators in the short run and return to the st
metabolite in the long run. 
We have reported a new family of dihydroxyhexanoic acid-derived oligom
600 MHz spectrom
of large-scale production of biopolyesters by a eukaryote. 
 
Experimental: 
General Experimental Procedures: NMR spectra of the oligomers (1) were 
measured using a Varian INOVA 600 MHz spectrometer equipped with a 5mm triple 
gradient HCN probe. All other NMR spectra were measured using a Varian System 
methanol solvent peaks at δ 3.31 and δ 49.0, respectively; chemical shifts of 3 were 
performed on a Micromass Quattro spectrometer operating in negative ion 
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electros ity 
n 
d 
 
CR873
us obtained, CR873 
genomic DNA was used as the template for a polymerase chain reaction with primers 
GCTGAACTTAAGC-3’) and LR5 (5’-TCCTGAGGGAAACTTCG-
he PCR 
 
pray mode. The high resolution mass spectrum of 3 was run by the Univers
of Illinois Mass Spectrometry facility. Adsorption chromatography was carried out o
silica gel 60 (FisherChemicals, 230-400 mesh). Size exclusion chromatography was 
carried out on Sephadex™ LH-20 (Amersham Biosciences). 
 
Fungal material: CR873 was isolated from the interior of a Manilkara sp. leaf 
harvested from the Guanacaste Conservation Area in Costa Rica. (Collection notes 
indicate that the leaf was uneaten, but brown around the edges.) Plant tissue was 
surface sterilized by successive 5-minute washes in 10% bleach, 70% ethanol, an
three fresh portions of sterile water. Five-mm squares of plant tissue were cut from the
surface-sterilized specimen and placed on PDA plates to promote fungal growth. 
CR873 was subcultured from the fungi that grew from these samples after two days 
and then successively subcultured to obtain a pure fungal culture. 
 
 rDNA Sequencing. Genomic DNA was extracted from lyophilized fungal 
tissue by grinding in liquid nitrogen followed by hot lysis (65 ºC, 0.5 % SDS), 
phenol/chloroform extraction, and ethanol precipitation. Th
LR0R (5’-ACCC
3’) to amplify a 900 base pair fragment of the large subunit ribosomal DNA. T
product was cloned and sequenced, and the consensus sequence used in a BLAST 
search to identify closely related fungi. 
 
Culture Conditions: Agar plugs of CR873 on potato dextrose agar were used to 
inoculate seed cultures in potato dextrose broth at 25 ºC. The four-day old seed 
cultures were then used to inoculate 10 L fermenter flasks containing potato dextrose
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broth. After fermenting for 7 days at 25 ºC, the fungal cultures were temporarily store
at -20 ºC prior to extraction.  
 
Extraction and isolation: Solid-phase extraction of a 20 L culture of CR873 grown in 
potato dextrose broth gave 5.39 g total organic extract. Size-exclusion 
chromatography on Sephadex LH-20 gave the poly(3,5-DHH
d 
) (1) as the first twenty 
fractions from the column (1.58 g total). 
73 
), 
 
, 
-2eq), 2.74 (dd, 
J2ax-2eq = 17.6 Hz, J2ax-3 = 5.1 Hz, 1H, H-2ax), 4.39 (dqd, J3-2ax = 5.1 Hz, J3-2eq = J3-4ax 
 J5-
O3, 
 
3,5-dihydroxyhexanoic acid δ-lactone (3) was obtained as an optically active clear 
glass, [α]
25
D +26.2 (c 0.2, CHCl3); IR (NaCl, thin film) νmax: 1708, 1387, 1258, 10
cm
-1;
 13C NMR (CDCl3, 600 MHz, δ): 170.2 (C-1), 72.1 (C-5), 62.9 (C-3), 38.4 (C-4
37.7 (C-2), 21.3 (C-6); 
1H NMR (CDCl3, 600 MHz, δ): 1.40 (d, J6-5 = 6.5 Hz, 3H, H-
6), 1.74 (ddd, J4ax-4eq = 14.5 Hz, J4ax-5 = 11.3 Hz, J4ax-3 = 3.3 Hz, 1H, H-4ax), 1.97
(dddd, J4eq-4ax = 14.5 Hz, J4eq-3 = 3.8 Hz, J4eq-5 = 3.0 Hz, J4eq-2eq = 1.8 Hz, 1H, H-4eq)
2.61 (ddd, J2eq-2ax = 17.6 Hz, J2eq-3 = 3.7 Hz, J2eq-4eq = 1.8 Hz, 1H, H
= J3-4eq = 3.8 Hz, J3-5 = 0.5 Hz, 1H, H-3), 4.85 (dqdd, J5-4ax = 11.2 Hz, J5-6 = 6.5 Hz,
4eq = 3.0 Hz, J5-3 = 0.5 Hz, 1H, H-5). HRMS-EI+ (m/z): [M + 1]  calcd for C
+
6H10
130.0630; found, 130.0631. 
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Chapter Four 
New Cytokinesis Inhibitory Cucurbitacins from Physocarpus capitatus 
 
 
ches 
t of many 
rotein e 
quired for other cellular processes, thus making small molecules a preferred tool 
(over genetics) for studying cytokinesis. 
Natural products have provided the vast majority of small molecule probes for 
studying the cell cycle and mitosis.
2, 3 The tubulin-interactive agents Taxol®,  
Figure 4.1. Anti-mitotic natural products. 
N
O O
Cytokinesis is the final step in the cell cycle whereby the cytoplasm pin
apart to form two daughter cells. This poorly understood process is the resul
s acting in a highly coordinated fashion.
1 Many of these same proteins ar p
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vincristine, and halichondrin B were n National Cancer Institute (NCI) 
projects lin B 
hich inhibit actin polymerization), and jasplakinolide (which induces actin 
olymerization) (Figure 4.1). 
t 
les 
stems Biology department, a high-
through
itosis proceeds as normal but cytokinesis is 
inhibited (dashed arrow), the result is a binucleate cell. 
 all discovered i
.
4 Natural product probes of actin include the cytochalasins and latruncu
(w
p
These natural products have played a crucial role in elucidating much of wha
is now known about cytokinesis, including the fundamental role of actin. However, 
there are hundreds of other proteins involved in cytokinesis, and the identity and ro
of many of these are still unknown. As part of a collaborative project with Ulrike 
Eggert and Tim Mitchison of the HMS Sy
put screen for inhibitors of cytokinesis was undertaken. Approximately 51,000 
small molecules were screened, including commercial libraries of “drug-like” 
compounds, combinatorial libraries, and crude natural product extracts provided by 
the NCI. 
Cytokinesis occurs at the end of mitosis, after the genetic material has already 
been duplicated, transported to opposite ends of the cell, and reorganized into new 
nuclei. Therefore, if cytokinesis is inhibited, the result is a cell with two nuclei. 
(Figure 4.2.) Binucleate cell formation is specific to only inhibitors of cytokinesis. The 
process is also irreversible, making a high-throughput screen possible. 
binucleate cell 
mitosis  cytokinesis 
 
Figure 4.2. Schematic of cell division. If m
44  
In this screen, Drosophila Kc167 cells were exposed to small molecules, 
allowed to undergo a complete cell cycle, fixed, and stained with 
tetramethylrhodamine-NHS ester (to visualize the cytoplasm) and Hoechst dye
visualize the DNA). Stained ce
 (to 
lls were imaged using automated fluorescence 
microsc
ity 
l 
s screened, they accounted for 25% of the hits. 
paration. Nineteen active fractions were examined by NMR and found to contain 
opy and scored by a combination of automated image analysis and visual 
inspection.
5 This whole-cell approach allowed for the possibility of discovering 
unknown targets, and molecules that hit should also have an improved chance of 
providing drug leads, since they have already demonstrated cell penetration and 
effectiveness in vivo.
6
A crude extract of Physocarpus capitatus (a.k.a. Pacific Ninebark, a conifer 
native to the western United States), showed strong cytokinesis-inhibitory activ
(Figure 4.3). Interestingly, although natural products represented only 5% of the tota
compound
Figure 4.3. Binucleate cells resulting from treatment with P. capitatus extract. 
The active P. capitatus extract was fractionated by several rounds of reverse-
phase and silica column chromatography, followed by reverse-phase HPLC 
se
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assorte ith a 
iscuous oxidases (a  
.
8 
 10 as 
 
Figure 4.4. tokinesis inhibitory cucurbitacins 
isolated from P. capitatus
Closer insp ra of the less 
active fractions revealed ) (Figure 4.4). A spin system 
4), 
and C-17 (δ 2.65 in 3, 2.49 in 4) revealed a site of oxidation at carbon C-15. HMBC 
correla
itacins 
 
3.98 in 3; 4.66 in 4) and H-16 (δ 5.33 in 3, δ 4.47 in 4) indicates that both hydroxyls 
d cucurbitacins. The cucurbitacins are a family of plant natural products w
common triterpene skeleton ‘decorated’ in various places by prom
common theme in natural products).
7 Selected cucurbitacins are shown in Figure 4.4
Comparison of chemical shifts to literature values revealed cucurbitacin F (1)
9,
the most potent cucurbitacin from P. capitatus, and the known cucurbitacin 23,24-
dihydrocucurbitacin F (2)
9, 11 was also observed (Figure 4.4). 
 Selected cucurbitacins (top), and cy
 (bottom). 
ection of the double quantum-filtered COSY spect
 two new cucurbitacins (3 and 4
connecting methine carbons C-15 (δ 3.98 in 3, 4.66 in 4), C-16 (δ 5.33 in 3, 4.47 in 
tions from protons H-16 of 3 (δ 5.33) and H-15 of 4 (δ 4.66) to acetate 
carbonyls at δ 170.8 and δ 171.2, respectively, suggested that the two cucurb
differ only in the site of acetylation. A NOESY correlation between protons H-15 (δ
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are on the same face. Remaining NMR chemical shifts indicated that the structures are 
in all other ways identical to cucurbitacin F. 
Table 4.1. Physocarpus capitatus
13C 
1H 
 NMR chemical shifts of cucurbitacins from   in 
CD3OD. Overlapping chemical shifts are indicated in italics. 
  1 2 3 4 
 
13C 
1H 
13C 
1H 
13C 
1H 
1 34.4  1.02,  1.80  1.02, 1.80 33.4 1.02, 1.78 34.4 33.4 1.02,  1.78
2 71.5  3.54  71.5 3.54  70.3 3.55  70.3 3.55 
3 81.9  2.85  81.9 2.85  80.7 2.85  80.7 2.85 
4 43.0  -  43.0 -  42.0 -  42.0 - 
5 142.5 -  142.5 -  140.9 -  140.9 - 
6 119.7 5.75  119.7 5.74 118.9 5.72 118.9 5.72 
7 24.6  1.97,  2.40 24.6 1.97, 2.40 22.1 2.32, 2.71 22.1 2.32,  2.71
8 44.2  1.93  44.2 1.93  43.1 2.11 43.2  2.11 
9 49.6  -  49.6 -  48.7 -  48.7 - 
10 34.9  2.48  34.9 2.48  33.8 2.49  33.8 2.49 
11 215.8 -  215.8 -  214.0 -  214.0 - 
12 49.7  2.55,  3.31 49.7 2.55, 3.31 48.4 2.57, 3.42 48.4 2.57,  3.42
13  48.8  - 48.9 - 47.5 - 47.5 - 
14  51.8  - 51.7 - 49.5 - 48.4  - 
15 46.4  1.39,  1.84 46.4 1.38,  1.82 75.0 3.98  79.7  4.66 
16  71.8  4.46 71.2 4.41 72.8 5.33 68.5  4.47 
17  59.3  2.60 59.0 2.57 53.2 2.65 56.9  2.49 
18  20.4  0.90 20.1 0.90 19.4 0.97 19.4  0.96 
78.5 - 78.5 - 
21  25.2  1.38 25.3 1.38 23.3 1.38 23.3  1.38 
22  2
23 1
25  71.3  - 70.7 - 70.5 - 70.5  - 
 
32       19.8 1.90 19.8  2.10 
19 20.3  1.07  20.3 1.07  18.9 1.09  18.9 1.09 
20  79.6  - 80.5 - 
04.7  - 216.9 - 202.8 - 203.3  - 
20.9 6.82  33.0 2.72,  2.85 119.4 6.80  119.2 6.80 
24 155.0 6.97  37.9 1.71,  1.72 155.2 7.04  154.4 6.98 
26  29.1  1.32 29.1 1.19 27.9 1.32 27.9 1.32 
27  29.1  1.33 29.1 1.19 28.1 1.34 28.1 1.34 
28 22.1  0.96  22.1 0.96  20.9 0.97  20.9 0.97 
29 25.2  1.17  25.2 1.17  24.0 1.16  24.0 1.16
30 28.9  1.30  28.9 1.30 11.6 1.20 12.8  1.31 
31       170.8 -  171.2 - 
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NMR inspection of the fractions from P. capitatus also revealed a new 
biphenyl glucoside (5), with the carbon skeleton shown in Figure 4.5. 
Fig e  e henyl g ide isolated fro  c us. 
 effects of c bitacins o  h e been reported in the 
lite u  the precis t n m ti uc
kn n. s , expos  H cells to  b s caused  
ag ga ls ure 4.6) inetic d o yrene- 
ac a d c ta   o n
not directly polymerize or d m ize actin. P ly, the cucurbitacins act on 
o f t n nv d lym a d depo z .
16  
Figure 4.6. Electron micrograph of cucurbitacin te a cells, expanded to show 
actin ‘hairball’ (courtesy of Peg Coughlin). 
O
O
O
O
HO
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gre te into clumps or ‘hairbal ’ (Fig . However, k ata fr m a p
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ne o he ma y proteins i olve  in actin po eriz tion an lymeri ation
-trea d HeL
O
O
OH
HO
OH
1
2
4
3
2'
1''
6''
5''
4''
6
5 1'
6'
5'
4'
3' 2'' 3''
5
48  
 In a genome-wide RNA interference (RNAi)
17 screen conducted 
simultaneously with the small-molecule screen, the actin hairball phenotype was not 
observed.
5 Since nearly all (about  Drosophila genome were 
effectively knocked out in the RNAi screen, the absence of this phenotype suggests 
that the cucurbitacins ma  of function in one of the proteins involved in 
actin polymerization. Wa ed that the effect is not reversible 
 some tolerance for 
structural variations. Studies are ongoing to find the target and mechanism of action 
for this interesting family of compounds. 
 
Experimental 
General Experimental Procedures.  H NMR and  C NMR spectra were obtained on 
a Varian INOVA 600 MHz spectrometer with standard pulse sequences. CD OD was 
used as solvent. Offline processing was conducted using Mestre-C NMR Software 
(Mestrelab Research, A Coruña, Spain; www.mestrec.com).  H and  C chemical 
shifts were referenced with the methanol solvent peaks at δ 3.31 and δ 49.05, 
respectively. LCMS data was obtained using a Micromass Platform LC-Z 
spectrometer, equipped with a Waters 2690 LC system and Waters 2690 photodiode 
array detector, and processed using MassLynx software (Waters Corporation, Milford, 
MA; www.waters.com). HPLC was carried out on an Agilent 1100 system equipped 
with diode array detector and operated with Chemstation software (Agilent 
Technologies). All HPLC separations were done using a Discovery HS-C18 column 
(Supelco, 250 x 10.0 mm, 5mm particle size) with a 4mL/min flow rate. Column 
.  
 
90%) of the genes in the 
y cause a gain
shout experiments show
and tests on other commercially-available cucurbitacins revealed
1 13
3
1 13
chromatography was carried out on silica gel 60 (FisherChemicals, 230-400 mesh) and 
octadecyl-functionalized silica gel (Aldrich)
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Plant m  capitatus 
 
s 
 step was again chromatographed on C18 
lica gel, this time eluting with 50% aqueous methanol to give four fractions. 
 mg) and 2 (231 mg) were combined and chromatographed on silica 
s 3 and 
(2), 
 (C-22), 
, 
8), 20.3 (C-19); 
1H NMR (CD3OD, δ): 6.97 (d, J = 15.5 Hz, 1H, H- 24), 6.82 (d, J = 
aterial. Approximately 18 g of an organic extract of Physocarpus
(NPID N102479) was provided by Gordon Cragg in the Natural Products Branch of 
the National Cancer Institute. The plant material was collected in Oregon. 
 
Isolation. The crude NCI extract (18 g) was dissolved in aqueous methanol (90%) and
partitioned against hexanes (700 mL x 3), then adjusted to 60% methanol and 
extracted with dichloromethane (1000 mL x 3). The dichloromethane layer (4.5 g) wa
chromatographed on C18 silica gel and five fractions eluted with a methanol/water 
step gradient. Fraction 2 (0.59 g) from this
si
Fractions 1 (412
gel using a dichloromethane/methanol step gradient to give seven fractions. Fractions 
4 (70 mg) and 5 (160 mg) were combined and subjected to RP-HPLC with an 
acetonitrile/water gradient, yielding nine fractions. Finally, fraction 4 (53 mg) was 
separated into eleven more fractions by RP-HPLC with a methanol/water gradient. 
Fraction 4 (16.9 mg) from this last column contained a mixture of cucurbitacin
4. Fraction 9 (2.4 mg) contained a mixture of 23,24-dihydrocucurbitacin F 
cucurbitacin F (1), and biphenyl (5), and fraction 10 (3.8 mg) contained pure 
cucurbitacin F (1). 
 
Cucurbitacin F (1): white solid; 
13C NMR (CD3OD, δ): 215.8 (C-11), 204.7
155.0 (C-24), 142.5 (C-5), 120.9 (C-23), 119.7 (C-6), 81.9 (C-3), 79.6 (C-20), 71.8 
(C-16), 71.5 (C-2), 71.3 (C-25), 59.3 (C-17), 51.8 (C-14), 49.7 (C-12), 49.6 (C-9)
48.8 (C-13), 46.4 (C-15), 44.2 (C-8), 43.0 (C-4), 34.9 (C-10), 34.4 (C-1), 29.1 (C-26), 
29.1 (C-27), 28.9 (C-30), 25.2 (C-21), 25.2 (C-29), 24.6 (C-7), 22.1 (C-28), 20.4 (C-
1
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15.5 Hz, 1H, H-23), 5.75 (d, J = 5.9 Hz, 1H, H-6), 4.46 (ddd, J = 9.0 Hz, J = 7.5 Hz, 
= 1.3 Hz, 1H, H-16), 3.54 (ddd, J = 11.5 Hz, J = 9.4 Hz, J = 4.2 Hz, 1H, H-2), 3.31 (*
H-12a), 2.85 (d, J = 9.4 Hz, 1H, H-3), 2.60 (d, J = 7.2 Hz, 1H, H-17), 2.55 
J 
, 
(d, J = 14.6 
z, 1H, H-12b), 2.48 (m, 1H, H-10), 2.40 (dd, J = 19.1 Hz, J = 8.1 Hz, 1H, H-7a), 
, 1.39 
 
-6), 
C-
 
 = 11.5 
4.2 Hz, H-2), 3.31 (*, H-12a), 2.85 (ddd, J = 18.0 Hz, J = 10.5 Hz, 
 = 5.3 Hz, H-23a), 2.72 (ddd, J = 18.0 Hz, J= 10.7 Hz, J = 5.2 Hz, H-23b), 2.57 (d, J 
 
H
1.97 (dd, J = 19.1 Hz, J = 5.9 Hz, 1H, H-7b), 1.93 (d, J = 8.1 Hz, 1H, H-8), 1.84 (dd, J 
= 13.3 Hz, J = 9.0 Hz, 1H, H-15a), 1.80 (dt, J = 12.3 Hz, J = 4.2 Hz, 1H, H-1a)
(d, J = 13.3 Hz, 1H, H-15b), 1.38 (s, 3H, H-21), 1.33 (s, 3H, H-27), 1.32 (s, 3H, H-
26), 1.30 (s, 3H, H-30), 1.17 (s, 3H, H-29), 1.07 (s, 3H, H-19), 1.02 (q, J = 12.3 Hz,
1H, H-1b), 0.96 (s, 3H, H-28), 0.90 (s, 3H, H-18). *Multiplicity and integration of H-
12a was obscured by the solvent peak. 
 
23,24-dihydrocucurbitacin F (2): (characterized as a mixture with 11 and 13) white 
solid; 
13C NMR (CD3OD, δ): 216.9 (C-22), 215.8 (C-11), 142.5 (C-5), 119.7 (C
81.9 (C-3), 80.5 (C-20), 71.5 (C-2), 71.2 (C-16), 70.7 (C-25), 59.0 (C-17), 51.7 (C-
14), 49.7 (C-12), 49.6 (C-9), 48.9 (C-13), 46.4 (C-15), 44.2 (C-8), 43.0 (C-4), 37.9 (
24), 34.9 (C-10), 34.4 (C-1), 33.0 (C-23), 29.1 (C-26), 29.1 (C-27), 28.9 (C-30), 25.3 
(C-21), 25.2 (C-29), 24.6 (C-7), 22.1 (C-28), 20.3 (C-19), 20.1 (C-18); 
1H NMR
(CD3OD, δ): 5.74 (d, J = 5.8 Hz, H-6), 4.41 (t, J = 8.1 Hz, H-16), 3.54 (ddd, J
Hz, J = 9.4 Hz, J = 
J
= 7.4 Hz, H-17), 2.55 (d, J = 14.6 Hz, H-12b), 2.48 (m, H-10), 2.40 (dd, J = 19.1 Hz, J
= 8.1 Hz, H-7a), 1.97 (dd, J = 19.1 Hz, J = 5.9 Hz, H-7b), 1.93 (d, J = 8.1 Hz, H-8), 
1.82 (m, H-15a), 1.80 (dt, J = 12.3 Hz, J = 4.2 Hz, H-1a), 1.72 (ddd, J = 15.7 Hz, J = 
10.5 Hz, J = 5.0 Hz, H-24a), 1.71 (*, H-24b), 1.38 (m, H-15b), 1.38 (s, H-21), 1.30 (s, 
H-30), 1.19 (s, H-26), 1.19 (s, H-27), 1.17 (s, H-29), 1.07 (s, H-19), 1.02 (q, J = 12.3 
51  
Hz, H-1b), 0.96 (s, H-28), 0.90 (s, H-18). *Multiplicity of H-12a was obscured by the 
solvent peak. Multiplicity of H-24b was obscured by overlap with H-24a. 
 
3 (characterized as a mixture with 4) white solid; 
13C NMR (CD3OD, δ): 214.0 (C-1
202.8 (C-22), 170.8 (C-31), 155.2 (C-24), 140.9 (C-5), 119.4 (C-23), 118.9 (C-6), 80.7 
(C-3), 78.5 (C-20), 75.0 (C-15), 72.8 (C-16), 70.5 (C-25), 70.3 (C-2), 53.2 (C-17), 
49.5 (C-14), 48.7 (C-9), 48.4 (C-12), 47.5 (C-13), 43.1 (C-8), 42.0 (C-4), 33.8 (C-10
33.4 (C-1), 28.1 (C-27), 27.9 (C-26), 24.0 (C-29), 23.3 (C-21), 22.1 (C-7), 20.9 (C-
28), 19.8 (C-32), 19.4 (C-18), 18.9 (C-19), 11.6 (C-30); 
1), 
), 
, 
4 Hz, 1H, H-23), 5.72 (dt, J = 6.2 Hz, J = 2.1 
z, 1H, H-6), 5.33 (t, J = 7.9 Hz, 1H, H-16), 3.98 (d, J = 8.1 Hz, 1H, H-15), 3.55 
-
1.6 
.7 
28), 19.8 (C-32), 19.4 (C-18), 18.9 (C-19), 12.8 (C-30); 
1H NMR (CD3OD, δ): 6.98 (d, 
1H NMR (CD3OD, δ): 7.04 (d
J = 15.4 Hz, 1H, H-24), 6.80 (d, J = 15.
H
(ddd, J = 11.6 Hz, J = 9.4 Hz, J = 4.2 Hz, 1H, H-2), 3.42 (d, J = 14.2 Hz, 1H, H-12a), 
2.85 (d, J = 9.4 Hz, 1H, H-3), 2.71 (ddd, J = 19.1 Hz, J = 6.2 Hz, J = 1.7 Hz, 1H, H-
7a), 2.65 (d, J = 7.6 Hz, 1H, H-17), 2.57 (d, J = 14.2 Hz, 1H, H-12b), 2.49 (m, 1H, H
10), 2.32 (m, 1H, H-7b), 2.11 (m, 1H, H-8), 1.90 (s, 3H, H-32), 1.78 (dt, J = 12.3 Hz, 
J = 4.2 Hz, 1H, H-1a), 1.38 (s, 3H, H-21), 1.34 (s, 3H, H-27), 1.32 (s, 3H, H-26), 1.20 
(s, 3H, H-30), 1.16 (s, 3H, H-29), 1.09 (s, 3H, H-19), 1.02 (dd, J = 12.3 Hz, J = 1
Hz, 1H, H-1b), 0.97 (s, 3H, H-18), 0.97 (s, 3H, H-28). HRESIMS (m/z): [M + Na]
+ 
calcd for C32H48O9 + Na, 599.3196; found, 599.3202. 
 
4 (characterized as a mixture with 3) white solid; 
13C NMR (CD3OD, δ): 214.0 (C-11), 
203.3 (C-22), 171.2 (C-31), 154.4 (C-24), 140.9 (C-5), 119.2 (C-23), 118.9 (C-6), 80
(C-3), 79.7 (C-15), 78.5 (C-20), 70.5 (C-25), 70.3 (C-2), 68.5 (C-16), 56.9 (C-17), 
48.7 (C-9), 48.4 (C-14), 48.4 (C-12), 47.5 (C-13), 43.2 (C-8), 42.0 (C-4), 33.8 (C-10), 
33.4 (C-1), 28.1 (C-27), 27.9 (C-26), 24.0 (C-29), 23.3 (C-21), 22.1 (C-7), 20.9 (C-
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J = 15.4 Hz, 1H, H-24), 6.80 (d, J = 15.4 Hz, 1H, H-23), 5.72 (dt, J = 6.2 Hz, J = 2.1 
Hz, 1H, H-6), 4.66 (d, J = 7.9 Hz, 1H, H-15), 4.47 (t, J = 7.7 Hz, 1H, H-16), 3.55 
dd, J = 11.6 Hz, J = 9.4 Hz, J = 4.2 Hz, 1H, H-2), 3.42 (d, J = 14.2 Hz, 1H, H-12a), 
z, 
 
), 
 
.4 Hz, H-6’’a), 3.68 (dd, J = 
2.0 Hz, J = 6.1 Hz, H-6’’b), 3.53 (dd, J = 9.1 Hz, J = 7.6 Hz, H-2’’), 3.48 (dd, J = 9.1 
(d
2.85 (d, J = 9.4 Hz, 1H, H-3), 2.71 (ddd, J = 19.1 Hz, J = 6.2 Hz, J = 1.7 Hz, 1H, H-
7a), 2.58 (d, J = 14.6 Hz, 1H, H-12b), 2.49 (d, J = 7.6 Hz, 1H, H-17), 2.49 (m, 1H, H-
10), 2.32 (m, 1H, H-7b), 2.11 (m, 1H, H-8), 2.10 (s, 3H, H-32), 1.78 (dt, J = 12.3 H
J = 4.2 Hz, 1H, H-1a), 1.38 (s, 3H, H-21), 1.34 (s, 3H, H-27), 1.32 (s, 3H, H-26), 1.31 
(s, 3H, H-30), 1.16 (s, 3H, H-29), 1.09 (s, 3H, H-19), 1.02 (dd, J = 12.3 Hz, J = 11.6
Hz, 1H, H-1b), 0.97 (s, 3H, H-28), 0.96 (s, 3H, H-18). HRESIMS (m/z): [M + Na]
+ 
calcd for C32H48O9 + Na, 599.3196; found, 599.3202. 
 
5: (characterized as a mixture with 1 and 2) white solid; 
13C NMR (CD3OD, δ): 150.6 
(C-3), 150.1 (C-4’), 147.8 (C-3’), 145.0 (C-5), 136.8 (C-1), 135.6 (C-4), 135.4 (C-1’
122.0 (C-6’), 116.8 (C-2’), 113.8 (C-5’), 107.8 (C-6), 102.8 (C-1’’), 102.3 (-OCH2O-),
101.8 (C-2), 78.1 (C-5’’), 77.7 (C-3’’), 75.0 (C-2’’), 71.6 (C-4’’), 62.5 (C-6’’), 57.0 
(5-OCH3), 56.7 (4’-OCH3); 
1H NMR (CD3OD, δ): 7.38 (d, J = 2.2 Hz, H-2’), 7.19 (dd, 
J = 8.4 Hz, J = 2.2 Hz, H-6’), 7.04 (d, J = 8.4 Hz, H-5’), 6.78 (d, J = 1.6 Hz, H-6), 
6.76 (d, J = 1.6 Hz, H-2), 5.95 (s, -OCH2O-), 4.96 (d, J = 7.6 Hz, H-1’’), 3.93 (s, 5-
OCH3), 3.89 (s, 4’-OCH3), 3.89 (dd, J = 12.0 Hz, J = 2
1
Hz, J = 8.7 Hz, H-3’’), 3.45 (m, H-5’’), 3.37 (dd, J = 9.8 Hz, J = 8.7 Hz, H-4’’). 
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55 Chapter Five 
TRPV4 Activators and Angiogenesis Inhibitors from Plants Used 
 
y of producing biologically useful 
traditio
ce 
shaped by theory, formal education, and a written, documented history—is an 
specially rich source of natural products, supplying 45% of the plant-based medicine 
arket.
2, 3 Recent studies on Chinese plants have yielded new immunosuppressant, 
antiarrhythmic, anesthetic, and anticancer compounds, yet the majority of Chinese 
medicinal plants have not been chemically and pharmacologically studied in detail,
4-6 
and broad-based screening of extracts from traditional Chinese medicinal plants 
should yield interesting new chemistry and biology. 
Unfortunately, certain features of crude natural product extracts in general, and 
plant extracts in particular, have made them difficult to adapt to modern screening 
methods. Plant extracts are especially complex, leading to a reasonable likelihood of 
one compound obscuring the activity of another in any given extract; and plants 
contain high concentrations of polyphenolic compounds which show nonspecific 
activity in many assays. 
Prefractionation is one solution to the problem of screening crude extracts. 
Plant polyphenols can be easily removed by solid-phase extraction, and 
                                                
 in Traditional Chinese Medicine
∗
 
Plants have a long and impressive histor
natural products, and even today some 80% of the earth’s inhabitants depend on 
nal medicine (primarily plants) for their primary health care.
1 Traditional 
Chinese medicine (TCM)—the product of thousands of years of human experien
e
m
 
∗ Reproduced in part with permission from: Smith, P. L., Maloney, K. N. Pothen, R. G., Clardy, J., 
Clapham, D. E. Journal of Biological Chemistry In press. Copyright [2006] American Society for 
Biochemistry and Molecular Biology. 
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chromatographic separation of the re t can significantly reduce the 
number of  
interference and shorter is
Our collaborators at the National Biodiversity Institute (INBio) in Costa Rica 
cently obtained the technology to facilitate rapid, large-scale prefractionation of 
natural t 
ganic 
y 
h 
is 
re 
uantities of each provided by Dr. David Eisenberg of Harvard 
Medica  
gically active 
maining extrac
 compounds per well, resulting in a lower probability of compound
olation times. 
re
 product extracts. This technology, in the form of a large modular instrumen
known as BioXplore©, was donated to INBio by Eli Lilly. Using BioXplore©, or
extracts of plant or fungal material are adsorbed onto solid support and thoroughl
washed with water to remove salts and saccharides. The clean extracts are eluted wit
ethanol and loaded onto a preparative-scale reverse-phase column. The extract 
separated into 48 fractions, and fractions of sufficient weight are shipped to Harvard 
Medical School where they are formatted for screening (Figure 5.1). 
plant material
salts, highly polar compounds 
UTION 
SPE resin 
insolubles, strongly adsorbed compounds 
1. WATER WASH 
2. EtOH EL
48 purified fractions
3. C-18 COLUMN 
Figure 5.1. Prefractionation of plant extracts using BioXplore©. 
Under a grant from the Starr Foundation, fifty Chinese medicinal plants we
selected and multigram q
l School’s Osher Institute. Prefractionation of these plants using BioXplore©
gave 1025 purified fractions for screening. In order to discover new biolo
plant natural products, and/or new uses for known natural products, we subjected this 
collection of prefractionated Chinese medicinal plants to a variety of investigator-
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initiated screens at the Institute of Chemistry and Cell Biology (ICCB) at Harvard
Medical School. This chapter describes the results obtained from two such scre
 
 
ens. 
TRPV4
 in pain 
ay have 
entually whole 
all molecules should provide 
a natural tool for understanding these channels. Additionally, small molecules can be 
ible with genetic 
approac
hol 
 channel activators 
Ion channel function is implicated in a host of diseases, including cystic 
fibrosis, heritable hypertension, and a variety of hereditary myopathies.
7 Among the 
most interesting and least understood of the ion channels are the transient receptor 
potential (TRP) channels. Upon activation, these channels open briefly, allowing a 
rapid influx of calcium that triggers signaling cascades within the cell. TRP channels 
act as the signal transducers that mediate the response to environmental stimuli—
including temperature, touch, pain, taste—on the organismal and cellular level.
8 The 
vanilloid receptor (TRPV1) is an example of a TRP channel involved
pathways, and other TRP channels are known to be overexpressed in certain types of 
cancer cells, suggesting that small molecule inhibitors of TRP channels m
implications for drug design. Both the function (sensation) and the corresponding 
ligand for most TRP channels are unknown.
9
TRP channels are the primary means by which cells (and ev
organisms) respond to noxious chemicals. Therefore, sm
introduced in a spatially and temporally controlled manner imposs
hes. 
Plants are a natural place to look for such a small molecule probe. Having 
evolved to discourage animals from eating them, plants produce a variety of the kind 
of noxious chemicals which are known to stimulate TRP channels, and the majority of 
known small molecule activators of TRP channels are plant-derived.
10 Capsaicin (the 
‘heat’ in chili peppers),
11 camphor (a numbing agent from evergreen trees),
12 ment
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(the cooling component in peppermint),
13, 14 and cinnamaldehyde (the pungent 
sensation of cinnamon)
15 are examples of plant-derived natural product activators of 
RP channels (that activate TRPV1, TRPV3, TRPM8, and TRPA1, respectively). 
TRPV4 is a member of the vanilloid family of TRP channels that is highly 
expressed in skin, kidney, lung, brain, smooth muscle, liver, and heart endothelium.  
TRPV4 is known to be activated by heat,  hypoosmolarity,  epoxyeicosatrienoic 
acids,  and 4α-phorbol 12,13-didecanoate.  Although functional studies, channel 
localization, and analysis of TRPV4-knockout mice suggest a role for TRPV4 in 
osmosensation,  pressure sensation,  nociception (pain perception),  and heat 
sensation,  the mechanistic details of these roles are still being investigated, and 
additional small molecule probes of this channel are desired. 
The calcium imaging assay shown in Figure 5.3 was used to screen the 
prefractionated Starr extracts for activators of TRPV4. Acetoxymethyl ester groups on 
the fluorophore Fluo4-AM facilitate entry into the cell (in this case, TRPV4 
overexpressing human embryonic kidney cells). Inside the cell the esters are cleaved, 
trapping the fluorophore. In the presence of a TRPV4 activator, calcium flows into the 
cell and is chelated by Fluo4, causing a dramatic (but short-lived) change in 
fluorescence. Due to the transient nature of the response, the necessary 
instrumentation for high-throughput screening is expensive and still only available in 
industrial settings. Therefore, we performed this screen in a low-throughput laboratory 
assay. The low-throughput nature of the screen underscored the importance of  
T
O OH
Figure 5.2. TRP channel activators from plants. 
16
17 18, 19
20 21
22, 23 24 25
26
H CO 3
HO
N
H
O
cinnamaldehyde menthol capsaicin
O
camphor
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choosing a library of compounds with a high probability of activating TRP chan
and for the reasons mentioned previously, we expected our collection of 
nels, 
prefractionated Chinese medicinal plants to be just such a library. 
 
mV 
was recorded. When 
TRPV4  much 
egative 
u), a root 
atory agent; 
hypertensive; Sophora sp. (shan dou gen), used as a respiratory relaxant and for its  
Fluo4-AM 
  Fluo4--AM  Fluo4 
Ca
2+
Fluo4-Ca  Fluo4 
add extract 
Ca
2+
HEK cell 
Figure 5.3. Calcium imaging assay for TRPV4 activation. 
Hits from this primary assay were subjected to an electrophysiologic assay
using the outside-out patch clamp technique shown in Figure 5.4. A pipet tip was 
inserted into HEK293T cells overexpressing TRPV4. A voltage ramp (from -100 
to +100 mV) was applied to the cell, and the resulting current 
 is closed, ions cannot flow into the cell, and the current does not change
in response to voltage (grey line). However, in the presence of a small molecule 
activator, TRPV4 opens, allowing calcium ions to flow into the cell when a n
voltage is applied and out of the cell when a positive voltage is applied (black line). 
Fractions from four Chinese medicinal plants showed activity in both primary 
and secondary TRPV4 activation assays. These were: Stellaria sp. (yin chai h
used in TCM as a coagulant, muscle relaxant, diuretic, and anti-inflamm
Fritillaria sp. (chuan bei mu), used as a cough suppressant, expectorant, and 
O O
F R
RO
N
OR
O
O
N
RO O
RO
RO
O
O
O
O O R = Fluo4-AM
R = H Fluo4
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anti-inflammatory, and hepatoprotective effects; and Andrographis sp. (chuan xin 
lian), known to have antipyretic, anti-inflammatory, and hepatoprotective effects. 
Figure 5.4. Electrophysiologic assay for TRPV4 activation. 
The Stellaria fraction was observed to be approximately 80% pure by NMR, 
and the 
1H NMR and LCMS revealed an unsaturated fatty acid with [M – 1]
- 279.1 
which we suspected to be linoleic acid. The 
1H NMR spectrum of the Stellaria fraction 
spiked with pure linoleic acid from Sigma-Aldrich confirmed the identification, and 
the commercial linoleic acid also potently activated TRPV4. The LCMS 
chromatogram of the Fritillaria fraction revealed a peak with the same retention time 
as linoleic acid, also with [M – 1]
- 279.1, and the NMR of that fraction also suggested 
that it contained linoleic acid. No chromatographic separation of these fractions was 
required. 
The double-quantum filtered 
1H-
1H COSY spectrum of the Sophora fraction 
revealed 2-3 glycosylated triterpenes. Chemical shifts of the major compound matched  
those of kaikasaponin III (1), a triterpene glycoside previously isolated from Sophora 
japonica.
27, 28
electrode 
pipette 
cell 
I
 
(
p
A
)
 
100  50  0 -50 -100
Voltage (mV) 
 control 
 activator 
Ca
2+ entering cell  Ca
2+ exiting cell  3000
2000
1000
0
-1000
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O
O
Figure 5.5. TRPV4 activators (1 and 2) and relatives (3 and 4) from TCM plants. 
The Andrographis fraction was the only fraction requiring chromatographic 
eparated by reverse-phase 
HPLC, and NMR chemical shifts for the major compound in the active fraction were 
found to match those of bisandrographolide A (2) (Table 5.1), a diterpene dimer 
previously identified in a screen for inducers of cell-differentiation in mouse myeloid 
leukemia cells.  A second round of HPLC separation gave pure bisandrographolide 
A, which activated TRPV4 with an EC  of 790-950 nM. Bisandrographolide A was 
the most potent of the compounds tested, and caused oscillation of the TRPV4 
channel, a phenotype which had not been previously observed (Figure 5.6). 
Bisandrographolide A was also tested against other TRPs: it neither activated nor 
blocked activation of TRPV1, TRPV2, or TRPV3 channels. Interestingly, pure 
samples of monomers andrographolide (3) and 14-deoxy-11,12-
didehydroandrographolide (4) did not cause TRPV4 activation. 
separation prior to structure elucidation. This fraction was s
29
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Table 5.1 lated 
from 
 
  
   13C
 
. 
1H and 
13C NMR chemical shifts (δ) of bisandrographolide A (2) iso
Andrographis sp. in CD3OD. 
 
1H 
13C
   1H
1     39
* 1.21 (m),  
1.48 (dt, J = 13.4, 3.2)
 
39.4  1’  1.2
*, 1.5
*
2      38
*
3   3.3
* (m)
  80.6  3’  3.4
*  80.8
  43.2
5   1.2
* 56.6  5’  1.28  (m)    55.5
6    1 .0
8   -  148.6   8’ -    149.8
10  
1 .4
1   122.2
1  130.5
1 2
15  4.87 72.2  15’ 5.24  (dd,  J = 2.0, 4.3)    83.0
1
17  
  * *
1 .1
1   (d,  J = 11.2), 
 (d, J = 11.2) 
64.6  19’ 3.36  (d,  J = 11.0),  
4.13 (d, J = 11.0) 
 64.8
20    0 .0
1.13 (m), 1.74 (m)  37.8   2’  1.1
*, 1.75 (m) 
4   -  43.2   4’ - 
.31 (m), 1.82 (m)  25.1   6’  1.42 (dd, J = 13.0, 4.3), 
1.83 (m) 
 24
7    1.95 (m), 2.39 (m)  39.0   7’  2.09 (m), 2.46 (m)    37.5
9    1.76 (m)  55.9   9’  2.41 (m)    62.5
-  40.3   10’ -    40.5
1    1.61 (m), 1.87 (m)  67.7   11’ 6.89 (dd, J = 10.3, 15.7)    137
2    2.95 (m)  39.2   12’ 6.16 (d, J = 15.7) 
3  -  134.6   13’ - 
4  7.57  (dt,  J = 0.9, 1.8)  150.6   14’ 7.39 (d, J = 2.0)    148.
 
6  -  175.5   16’ -   173.5
4.49,  4.85 108.0  17’ 4.5 , 4.8  109.0
8    1.17 (s)  23.2   18’ 1.23 (s)    23
9  3.40
4.06
.65 (s)  15.0   20’ 0.86 (s)    16
 
* Obscured by overlap with other signals. 
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Figure 5.6. Electrophysiologic data for bisandrographolide A (2). 2 was added at 130 
seconds, causing TRPV4 to open, then oscillate for several minutes before fully 
Figure 5.7. Proposed mechanism for formation of bisandrographolide A (2). 
O
HO
HO
O
closing. 
Interestingly, bisandrographolide A was originally isolated along with two 
diasteromers, bisandrographolides B and C, differing in the stereochemistry at the site 
of dimerization.
29 The authors propose a biosynthetic origin for these dimers by a 
mechanism such as that shown in Figure 5.7, whereby a stabilized 12-cation 
intermediate (5) is attacked by the enol lactone (6) (itself formed by dehydration of 
andrographolide (3)). 
O
HO
HO
O
H
H
O
O
HO
HO
H
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While we agree with the proposed mechanism, we argue that rather than 
rming biosynthetically, the dimers might form as artifacts of the isolation procedure. 
his view is supported by the isolation of the different diastereomers in similar yields, 
 observat n of Matsuda et al. that andrographolide (3) is rapidly converted 
under mild reaction conditions (Figure 5.8).
g r sion of a rap olid tate (6-Ac)
g o
 exis
er  n ling
h ot well understo though angiogenesis is a normal part of 
bryo development and healing  n i jury, im ulation of angiog e
is imp r of conditions including atherosclerosis, psoriasis, 
thma, and cancer.
30
l organisms for studying angiogenesis. Their 
circulatory system and other organ systems develop within 48-72 hours and show 
remarkable similarity to those of mammals.
31 The majority of human genes studied to 
date (including those known to be involved in angiogenic signaling) have homologous 
genes in zebrafish.
32 Furthermore, the transparency of the zebrafish embryo makes it 
easy to observe interesting vascular phenotypes while its miniature size and 
O
fo
T
and by the io
to the enol lactone diacetate (6-Ac) 
29
Fi u e 5.8. Facile conver ndrog h e (3) to enol lactone ace . 
 
An i genesis inhibitors 
Angiogenesis is the process by which new blood vessels form from ting 
vessels. This process is regulated by a numb of ki ases in a complex signa  
pat way that is n od. Al
em after a n proper reg en sis 
licated in a numbe
rheumatoid arthritis, as
Zebrafish are excellent mode
O
HO
HO
H
HO
3
O
O
O O
AcO
AcO
H
O
N
RT h , 1 6-Ac
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permeability to small molecules added to the water greatly facilitates small-molecule 
screens,
33 34-36
Our collabo
Institute designed a m
intersegme Tg(Fli1-
GFP) zebrafish was used highly expressed in 
endothelial cells, and green fl ession in these transgenic 
FP) 
zebrafish embryos in 96-well plates and the zebrafish blood vessels were visualized 
using a ral 
els. D-
F) Views of Tg(Fli1-GFP) embryo treated with Stellaria extract showing vascular 
abnormalities including thin, misguided, and absent intersegmental vessels. 
 as is evident in several recent studies.
rators Pete Bayliss and Tom Roberts of the Dana Farber Cancer 
edium-throughput assay that allowed visualization of 
ntal vessel development in zebrafish (Figure 5.9a-c). A transgenic 
. (Fli1 is a transcription factor that is 
uorescent protein (GFP) expr
fish results in fluorescent blood vessels.
37) The prefractionated traditional Chinese 
medicinal plant extracts were added to the water surrounding 3-day-old Tg(Fli1-G
 fluorescence microscope. The embryos were also visually inspected at seve
time points and any interesting phenotypic changes noted. 
Figure 5.9. A) 3-day old Tg(Fli1-GFP) zebrafish embryo. B) Fluorescent blood 
vessels in Tg(Fli1-GFP) embryo. C) Expanded view of fluorescent blood vess
66  
A fraction from Stellaria sp. (yin chai hu) (a more polar fraction than the 
that activated TRPV4) caused severe vascular abnormalities, pericardial edema, and 
dorsal curvature in zebrafish embryos (Figure 5.9d-f). Interestingly, Stellaria is a 
known coagulant, and is prescribed in China for nosebleeds and heavy menstrual flow.
Misguided vessel formation (as shown in Figure 5.9e) represented a novel phenoty
one 
 
pe; 
it had neither been reported in the literature nor previously observed in the Roberts 
lab. The 
1
identified the m
1H dqfCOSY 
and 
1H-
13
Hydroferulic acid from
concentration of approxim
Figure
cular 
re 
he most 
re (Figure 5.11). 
ng 
ur 
p
 
H NMR spectrum of the active fraction showed it to be 90% pure, and I 
ajor compound as hydroferulic acid (7) based on the 
1H-
C HMBC spectra without any further chromatographic separation. 
 Alfa Aesar was confirmed to cause the phenotype at a 
ately 100μM. 
O
 5.10. Inhibitors of angiogenic signaling in zebrafish. 
In an effort to identify an inhibitor that was more potent in causing the vas
guidance phenotype without causing dorsal curvature, 45 related compounds we
tested in the assay. Cinnamaldehyde (8) was the most potent, showing the desired 
vascular phenotype at a concentration of 1μM, while benzaldehyde (9) was t
specific; causing almost no dorsal curvatu
These results showed that prefractionation of plant extracts prior to screeni
dramatically reduced the time required for isolation and structure elucidation. In fo
of the five extracts analyzed, the active com ound was identified without any further 
chromatographic separation. In the case of the TRPV4 activating Stellaria extract, the 
active compound (bisandrographolide A) was identified after a single chromatography
HO
O O O
79 8
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step. The total time from identification of the active extract to structure elucid
was less than one week in each case, and in one case was less than 24 hours. 
ation 
 
quences operating at 
). 
Figure 5.11. Tg(Fli1-GFP) zebrafish embryo treated with benzaldehyde. 
a Varian INOVA NMR spectrometer with standard pulse se
Furthermore, the biology discovered using these plant extracts proved to be 
novel and interesting, although the chemistry was not new. In both the TRPV4 channel 
screen and the angiogenesis screen, new phenotypes were observed that were not 
observed with any other compounds tested, and which had not been previously 
reported in the literature. By applying the same prefractionation strategy to less-
studied organisms – as is now being done in the Clardy Lab with endophytic fungi 
from Costa Rica – we expect to discover more new biology and new chemistry. 
Experimental 
General Experimental Procedures. 
1H NMR and 
13C NMR spectra were obtained on 
500MHz. CD3OD was used as solvent. Offline processing was conducted using 
Mestre-C NMR Software (Mestrelab Research, A Coruña, Spain; www.mestrec.com
68  
LCMS 
x 
tion and 
chool’s 
 
performed at  
ted using methanol with 
grinding. The extract from each plant was evaporated in a minimum volume of 
methan
ed 
ns 
for integration into their 
screeni
 
data was obtained using a Micromass Platform LC-Z spectrometer, equipped 
with a Waters 2690 LC system and Waters 2690 photodiode array detector, and 
processed using MassLynx software (Waters Corporation, Milford, MA; 
www.waters.com). HPLC was carried out on an Agilent 1100 system equipped with 
diode array detector and operated with Chemstation software (Agilent Technologies). 
All HPLC separations were done using a Discovery HS-C18 column (Supelco, 250 
10.0 mm, 5mm particle size) with a 4mL/min flow rate. 
 
Plant Material. Fifty Chinese medicinal herbs were selected for prefractiona
multigram samples of each provided by David Eisenberg of Harvard Medical S
Osher Institute. 
Extraction and Prefractionation. Extraction and prefractionation steps were 
 the Instituto Nacional de Biodiversidad (INBio) in Costa Rica. Gram
quantities of each of the Chinese medicinal plants were extrac
ol and adsorbed onto HP-20. The resin was washed with deionized water and 
extracted with ethanol. This solution was adjusted to 20% aqueous ethanol and load
onto a 500 mL RP-C18 column, where it was fractionated into 48 fractions. Fractio
of sufficient weight (>20mg, as judged by ELSD), were evaporated, reconstituted in 
DMSO, arrayed in 96-well plates, and shipped to the ICCB 
ng platform. 
 
Isolation. The active fraction from Andrographis (Starr C008 fraction 20, 15 mg) was
subjected to two rounds of RP-HPLC using an acetonitrile/water gradient to afford 
pure 1 (1.08mg). The active fractions from Sophora (Starr C024 fraction 22, 4.0 mg), 
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Stellaria (Starr C033 fraction 32, active in the TRPV4 assay, 7.3 mg; and Starr C033
fraction 10, active in the angiogenesis assay, 6.9 mg) and Fritillaria (Starr C0
 
06 
fraction 31, 15.1 m
 
Table 5.1. E
 
Kaikasaponin III (4 δ): 
 101.9 (C-1’’’), 
 40.2 (C-4), 
38.4 (C-17), 37.7 (C-1), 34.2 (C-9), 33.9 (C-6), 32.4 (C-29), 31.1 (C-20), 29.7 (C-16), 
28.9 (C-30), 28.5 (C-23), 26.7 (C-15), 25.1 (C
3
J = 
.59 (H-7), 1.57 (H-9), 1.57 (H-6a), 1.45 (H-21a), 1.40 (H-6b), 1.33 (H-21b), 1.26 (d, 
’’), 1.13 (s, H-27), 1.11 (s, H-23), 1.04 (H-15b), 1.01 (s, H-30), 0.99 
g) were not subjected to any further chromatography. 
Bisandrographolide D (1): white solid; 
1H and 
13C NMR (CD3OD, 500 MHz), see 
SIMS [M+1]
+ 665.53. 
): yellow amorphous solid; 
13C NMR (CD3OD, 500 MHz, 
177.8 (C-6’), 144.8 (C-13), 123.6 (C-12), 105.6 (C-1’), 102.6 (C-1’’),
92.0 (C-3), 78.4 (C-2’), 78.4 (C-3’), 77.0 (C-2’’), 76.9 (C-5’’), 76.9 (C-22), 75.9 (C-
3’’), 74.1 (C-4’’’), 71.9 (C-3’’’), 70.8 (C-4’’), 69.4 (C-5’’’), 62.7 (C-6’’), 56.9 (C-5), 
48.9 (C-7), 47.2 (C-19), 46.3 (C-18), 43.1 (C-14), 42.0 (C-21), 40.5 (C-8),
-27), 24.3 (C-11), 20.2 (C-28), 18.0 (C-
6’’’), 17.3 (C-25), 16.7 (C-24), 16.1 (C-26); 
1H NMR (CD OD, 500 MHz, δ): 5.25 (t, 
J = 3.0 Hz, H-12), 5.18 (d, J = 1.5 Hz, H-1’’’), 4.81 (d, J = 7.3 Hz, H-1’’), 4.46 (d, 
7.2 Hz, H-1’), 4.14 (m, H-5’’’), 3.92 (m, H-2’’’), 3.78 (C-6’’a), 3.75 (H-3’’’), 3.74 (H-
4’’), 3.70 (H-2’), 3.67 (H-2’’), 3.61 (H-3’), 3.60 (H-6’’b), 3.58 (H-3’’), 3.43 (H-22), 
3.42 (H-5’’), 3.39 (H-4’’’), 3.18 (dd, J = 11.2 Hz, J = 4.2 Hz, H-3), 2.27 (m, H-5’), 
2.05 (m, H-18), 1.91 (H-11a), 1.86 (H-11b), 1.75 (H-19a), 1.74 (H-16), 1.74 (H-15a), 
1
J = 6.1 Hz, H-6’
(s, H-26), 0.98 (s, H-25), 0.96 (H-19b), 0.92 (s, H-29), 0.89 (s, H-24), 0.84 (s, H-28), 
0.78 (H-5); ESIMS [M-1]
- 925.41. 
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Hydroferulic acid (5): white crystalline solid;
 13C NMR (CD OD, 500 MHz, δ): 
177.1 (C-1), 148.7 (C-3’), 145.7 (C-4’), 133.7 (C-1’), 121.4 (C-6’), 115.9 (C-5’),
112.8 (C-2’), 56.2 (OMe), 37.2 (C-2), 31.6 (C-3); 
3
 
MHz, δ): 
1H NMR (CD OD, 500
6.80 (1H, d, J = 2.2 Hz, H-2’), 6.69 (1H, d, J = 8.1 Hz, H-5’), 6.64 (1H, dd, J = 8.1 
Hz, J = 2.2 Hz), 3.83 (3H, s, OMe), 2.82 (2H, t, J = 7.7 Hz, H-3), 2.55 (2H, t, J = 7.9 
Hz, H-2). 
3
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Appendix A 
Isolation of 14-Deoxy-11,12-didehydroandrographolide,  
an Inhibitor of FtsZ from Andrographis Sp. 
protein
alled 
the Z-r
accomp mation of two 
new an the eukaryotic cell division 
regulation. 
y 
into fila e release of inorganic phosphate resulting from this GTP-ase activity 
 
for FtsZ activity.
7 A cell-based screen that exploits the role of FtsZ in cell division has 
also be hen rod-shaped bacteria (such as B. subtilis and E. 
inhibiti
8 us 
phenoty
small molecule inhibitors of cell division. 
 
 
Cell division in all organisms is a carefully regulated process involving many 
s acting in a highly coordinated fashion. In bacteria, the most abundant cell 
division protein is the structural protein FtsZ, which self-assembles into a ring (c
ing) in the center of a dividing bacterial cell. Contraction of the z-ring 
anied by cell wall synthesis leads to cell fission and the for
daughter cells.
1 Because of its importance to bacteria, FtsZ has become a target for 
tibiotics.
2-6 FtsZ is also a structural homolog to 
protein (and anticancer drug target) tubulin, making it relevant for studies of cell cycle 
Like tubulin, FtsZ binds to and hydrolyzes GTP in the process of self-assembl
ments. Th
can be easily assayed using radiolabeled GTP, providing a convenient in vitro screen
en described.
2 Interestingly w
coli) are prevented from undergoing cell division (for example, as a result of FtsZ 
on), the cells continue to replicate their genetic material and elongate into 
filamentous cells.  These cells eventually become unstable and lyse. This filamento
pe is easily observable under a microscope and serves as a useful assay for 
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In collaboration with the National Biodiversity Institute in Costa Rica we 
tionated a collection of fifty Chinese medicinal plants for testing in a variety o
ator-initia
prefrac f 
investig ted screens at the Institute of Chemistry and Cell Biology (ICCB) at 
and Jar
Figure A.1. Structure of 14-deoxy-11,12-didehydroandrographolide (1), an inhibitor 
of FtsZ isolated from Andrographis sp. 
One fraction from Andrographis sp. (chuan xin lian) showed strong activity 
against FtsZ in both in vitro and in vivo assays. After a single separation step, I 
identified the major compound in the fraction as 14-deoxy-11,12-
didehydroandrographolide (Figure A.1) by NMR spectroscopy. Purified 14-deoxy-
11,12-didehydroandrographolide (1) was confirmed to be responsible for the activity 
of the fraction against FtsZ. Although 1 has been previously reported as a metabolite 
of Andrographis,
9 its FtsZ inhibitory activity was unknown. The complete isolation 
and identification of the active compound took a mere 2 days, compared with several 
months for compounds isolated from crude extracts. 
 
Experimental 
General Experimental Procedures. 
1H NMR and 
13C NMR spectra were obtained on 
a Varian INOVA NMR spectrometer with standard pulse sequences operating at 500 
MHz. CD3OD was used as solvent. HPLC was carried out on an Agilent 1100 system 
O
Harvard Medical School. These prefractionated extracts were screened by Alan Hebert 
ed Shaw of the ICCB for inhibitors of FtsZ. 
O
HO
H
HO
1
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equipped with a diode array detector and operated with Chemstation software (Agilent 
Technologies). HPLC separation was do covery HS-C18 column 
(Supelco, 250 x
 
Plant Material. Fifty Chinese medicinal herbs were selected for prefractionation and 
multigram samples of each provided by David Eisenberg of Harvard Medical School’s 
Osher I
ram 
with 
d 
L RP-C18 column, where it was fractionated into 48 fractions. Fractions 
of suffi
ure 
, 
6.8 (C-14), 136.5 (C-11), 129.6 (C-13), 
122.7 (C-12), 109.3 (C-17), 81.3 (C-3), 71.7 (C-15), 65.1 (C-19), 62.9 (C-9), 55.8 (C-
ne using a Dis
 10.0 mm, 5mm particle size) with a 4mL/min flow rate. 
nstitute. 
 
Extraction and Prefractionation. Extraction and prefractionation steps were 
performed at the Instituto Nacional de Biodiversidad (INBio) in Costa Rica. G
quantities of each of the Chinese medicinal plants were extracted using methanol 
grinding. The extract from each plant was evaporated in a minimum volume of 
methanol and adsorbed onto HP-20. The resin was washed with deionized water an
extracted with ethanol. This solution was adjusted to 20% aqueous ethanol and loaded 
onto a 500 m
cient weight (>20mg, as judged by ELSD), were evaporated, reconstituted in 
DMSO, arrayed in 96-well plates, and shipped to the ICCB for integration into their 
screening platform. 
 
Isolation. The active fraction from Andrographis (Starr C008, fraction 18; 50 mg) was 
subjected to a single round of RP-HPLC using 65% CH3CN/H2O eluent to afford p
11,12-didehydroandrographolide (1) (13.2 mg). 
 
14-deoxy-11,12-didehydroandrographolide (1): white powder; 
13C NMR (CD3OD
500MHz, δ): 175.0 (C-16), 150.2 (C-8), 14
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5), 43.6 (C-10), 39.8 (C-4), 39.5 (C-1), 37.9 (C-7), 28.6 (C-2), 24.4 (C-6), 23.4 (C-18) 
(d, J = 11.1 Hz, 1H, H-19), 3.39 (*, H-3), 3.38 (*, H-18b), 2.45 (ddd, J = 13.6 Hz, J = 
4.3 Hz, J = 2.4 Hz, 1H, H-7a), 2.38 (d,   = 10.0 Hz, 1H, H-9), 2.08 (m, 1H, H-7b), 
1.83 (m, 1H, H-6a), 1.74 (dd, J  = 2.0 Hz, 1H, H-2a), 1.70 (m, 1H, H-2b), 
1.48 (dt, J = 13.6 Hz, J J = 12.9 Hz, J = 4.3 Hz, 1H, H-
6b), 1.27 (dd, J = 12.9 Hz, J = 2.5 Hz, 1H, H-5), 1.23 (s, 3H, H-18), 1.20 (*, H-1b), 
0.84 (s, 3H, H-20). * Integrals and coupling constants obscured by overlap from other 
signals. 
16.3 (C-20); 
1H NMR (CD3OD, 500 MHz, δ): 7.44 (t, J = 2.1 Hz, 1H, H-14), 6.86 (dd, 
J = 15.7 Hz, J = 10.0 Hz, 1H, H-11), 6.16 (d, J = 15.7 Hz, 1H, H-12), 4.87 (d, J = 2.1 
Hz, 2H, H-15), 4.76 (q, J = 1.7 Hz, 1H, H-17a), 4.50 (q, J = 1.7 Hz, 1H, H-17b), 4.13 
J
 = 3.5 Hz, J
 = 3.5 Hz, 1H, H-1a), 1.41 (qd, 
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Sequence B.1. FA39 rDNA sequence
TT
GGAA T
CGCCG
AATGGGAGGTAAAT
AAAT
TGTAGTTGCTTATCCGGACTTTTGTCCGGTGCACTCTTCTGCGGGCAGGCC
AGCA C
GGGG CC
GCGC CGTCTTGA
CCCCA
CATCGAC GT
AACTC A
TTTGGGCATAGGGGCGAAAGACTAATCGAACTATCTAGTAGCTGGTTCCTG
CCGA
 
 
GAGHGAAGCGGCAACAGCTCAAATTTGAAATCTGGCTCTTTCAGGGTCCG
AGTTGTAATTTGCAGAGGGCGCTTTGGTGTTGGCAGCGGTCCAAGTTCC
CAGGACGTCACAGAGGGTGAGAATCCCGTACGTGGTCGCTAGCCT
TGTAAAGCCCCTTCGACGAGTCGAGTTGTTTGGGAATGCAGCTCTA
TTCTTCTAAAGCTAAATACTGGCCAGAGACCGATAG
CGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTTGGAAAGAGAGTC
AGCACGTGAAATTGTTGAAAGGGAAGCGCTTGCAGCCAGACTTGCC
TCAGTTTGGGSCGGTTGGATAAAGGTCTCTGTCATGTACCTCTCTT
AGAACTTATAGGGGAGACGACATGCAACCAGCCTGGACTGAGGT
ATCTGCTAGGATGCTGGCGTAATGGCTGKYAAGCGGCC
AACACGGACCAAGGGAGTCTAACATCTATGCGAGTGTTTTGGGTGTCAAG
GACGCGTAATGAAAGTGAACGGAGGTGGGAACCCTTTGGGTGCAC
CGATCCTGRTGTCTTCGGATGGATTTGAGTAAGAGCATGGCT
TGGGACCCGAAAGATGGTGAACTATGCTTGAATAGGGTGAAGCCAGAGGA
TGGTGGAGGCTCGCAGCGGTTCTGACGTGCAAATCGATCGTCAA
AGTTTCCCTCAGGA 
82  
Seqence B.2. CR873 rDNA sequence 
 
ACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACCAACAG
GGAT GCGGCAAAAGCTCAAATTTGAAAT
CTGGCCCTAGCGGTCCGAGTTGTAATTTGCAGAGGATGCTTTTGGTGCGGT
GCCTTCCGAGTTCCCTGGAACGGGACGCCATAGAGGGTGAGAGCCCCGTA
CGGTTGGATACCTAGCCTCTATATAGCTCCTTCGACGAGTCGAGTAGTTTG
GGAATGCTGCTCTAAATGGGAGGTAAATTTCTTCTAAAGCTAAATACCGGC
CAGAGACCGATAGCGCACAAGTAGAGTGATCGAAAGATGAAAAGCACTTT
GAAAAGAGGGTTAAATAGCACGTGAAATTGTTGAAAGGGAAGCGTTTGCG
ACCAGACCTTCTCCCAGGGGGATCAACCGCTGTTCTCAGCGGTGCACTCCC
CCTGGTTTAGGCCAGCATCGGT GGGATAAAGGCCTGGGGAA
CGTAGCTCTTTAGGGAGTGTT CGTAATACCCTTCAGGGGA
CCGAGGACCGCGCTTCGGCAAGGATGCTGGCGTAATGGTCGTCAACGACC
CGTCTTGAAACACGGACCAAGGAGTCGAACATTTGTGCGAGTGTTTGGGT
GTTAAACCCTCACGCGTAATGAAAGTGAACGGAGGTGAGAGCCTTAGGGT
GCATCATCGACCGATCCTGATGTCTTCGGATGGATTTGAGTAAGAGCATAA
CTGTTCGGACCCGAAAGATGGTGAACTATGCGTGGATAGGGTGAAGCCAG
AGGAAACTCTGGTGGAGGCTCGCAGCGGTTCTGACGTGCAAATCGATCGT
CAAATCTGCGCATGGGGGCGAAAGACTTATCGAACCATCTAGTAGCTGGT
TACCGCCGAAGTTTCCCTCAGGA 
TGCCCTAGTAACGGCGAGTGAA
TCTCTTAGG
ATAGCCCCTAG
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STAT3 inhibition data 
 
 
Table C.1. Whole cell lysate preparations. 
STAT3 7  μl U266 whole cell lysate + 20 μl complete lysis buffer 
Table C.2. Inhibition of STAT3 made from U266 whole cell lysate by the 
 
STAT3 2  μl Hep G2 (IL-6, 100 ng/ml) whole cell lysate + 25 μl complete lysis 
buffer 
STAT1 α 2  μl U937 (INFγ + TPA) whole cell lysate + 25 μl complete lysis buffer 
STAT5 α 2  μl Nb2 (prolactin) whole cell lysate + 25 μl complete lysis buffer 
 
 
phaeosphaerides. 
 
conc (μg/mL)  500  250  125  63 31 16 0 
phaeosphaeride A (4)  0.16 0.38 0.60 0.79 0.91 0.94 1.03 
phaeosphaeride B (5)  0.85 0.91 0.83 0.81 0.81 0.85 0.81 
 
 
Table C.3. Selectivity of phaeosphaeride A against STAT1, STAT3, and STAT5 with
various whole cell lysates. 
 
conc (μg/mL)  500 250 125 63  31  16  0 
 
U266/STAT3  0.16 0.38 0.60 0.79 0.91 0.94 1.03 
U937/STAT1  0.5178 0.5004 0.5748 0.5599 0.5701 0.5668 0.5975 
Nb2/STAT5  0.5764 0.4527 0.5593 0.5449 0.6452 0.6286 0.561 
 
 
Table C.4. Phaeosphaeride A inhibits STAT3 made from HepG2 whole cell lysate. 
 
HepG2/STAT3  0  0  0.043 0.079 0.081 0.116 
conc (μg/mL) 1000  500  250  125  63  0 
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HMBC spectrum of phaeosphaeride A in DMSO-d6
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1H NMR spectrum of phaeosphaeride B in DMSO-d6  
O
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gHMBC spectrum of phaeosphaeride B in DMSO-d6
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1H NMR spectrum of mono-p-bromobenzoyl derivative of phaeosphaeride A in 
CD3OD 
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gHMBC spectrum of mono-p-bromobenzoyl derivative of phaeosphaeride A in 
D3OD  
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1H NMR spectrum of tri-p-bromobenzoyl derivative of phaeosphaeride A in CD3OD 
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gHMBC spectrum of tri-p-bromobenzoyl derivative of phaeosphaeride A in CD3
 
OD 
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1H NMR spectrum of dihydroxyhexanoic acid oligomers in CD3OD 
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gHMBC spectrum of dihydroxyhexanoic acid oligomers in CD3OD 
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1H spectrum of (3R,5R) 3,5-dihydroxyhexanoic acid δ-lactone in CDCl3
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13C NMR spectrum of (3R,5R) 3,5-dihydroxyhexanoic acid δ-lactone in CDCl3
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1H NMR spectrum of new cucurbitacins in CD3OD. 
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HMBC spectrum of new cucurbitacins in CD3OD. 
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1H NMR spectrum of cucurbitacin F in CD3OD 
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HMBC spectrum of cucurbitacin F in CD3OD. 
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1H NMR spectrum of cucurbitacin F + dihydrocucurbitacin F + biphenyl mixture in 
D3OD. 
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HMBC spectrum of cucurbitacin F + dihydrocucurbitacin F + biphenyl mixture in 
D3OD. 
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1H NMR spectrum of Starr fraction C024f22 containing kaikasaponin III in CD3OD 
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HMBC spectrum of Starr fraction C024f22 containing kaikasaponin III in CD3OD. 
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1H NMR spectrum of bisandrographolide A in CD3OD. 
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HMBC of bisandrographolide A in CD3OD. 
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1H NMR spectrum of Starr fraction C033f10 containing hydroferulic acid in CD3OD. 
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HMBC spectrum of Starr fraction C033f10 containing hydroferulic acid in CD3OD. 
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1H NMR spectrum of 11,12-didehydroandrographolide in CD3OD 
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13C NMR spectrum of 11,12-didehydroandrographolide in CD3OD 
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